22_CD 17h_JJ NOTES_NNS TO_TO GROUP_NNP FINANCIAL_NNP STATEMENTS_NNP 31_CD December_NNP 2002_CD 1_CD Accounting_NN policies_NNS A_DT summary_NN of_IN the_DT more_RBR important_JJ accounting_NN policies_NNS ,_, which_WDT have_VBP been_VBN reviewed_VBN by_IN the_DT Board_NNP of_IN Directors_NNS in_IN accordance_NN with_IN Financial_NNP Reporting_NNP Standard_NNP FRS_NNP 18_CD ,_, Notes_NNP to_TO Group_NNP financial_JJ statements_NNS Accounting_NNP Policies_NNS ,_, and_CC have_VBP been_VBN consistently_RB applied_VBN ,_, is_VBZ set_VBN out_RP below_IN ._.
FRS_NNP 19_CD ,_, Deferred_NNP Tax_NNP ,_, has_VBZ been_VBN adopted_VBN in_IN the_DT year_NN ,_, but_CC has_VBZ had_VBN no_DT impact_NN on_IN the_DT amounts_NNS The_DT notes_NNS to_TO Group_NNP financial_JJ statements_NNS included_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN and_CC balance_NN sheet_NN ._.
are_VBP intended_VBN to_TO provide_VB additional_JJ analysis_NN and_CC detail_NN required_VBN to_TO meet_VB Basis_NN of_IN accounting_NN statutory_JJ obligations_NNS ._.
The_DT preparation_NN of_IN our_PRP$ financial_JJ statements_NNS requires_VBZ us_PRP to_TO make_VB estimates_NNS and_CC judgments_NNS that_WDT affect_VBP the_DT reported_VBN amount_NN of_IN net_JJ assets_NNS at_IN the_DT date_NN of_IN our_PRP$ financial_JJ statements_NNS and_CC the_DT reported_VBN amounts_NNS of_IN revenues_NNS and_CC expenses_NNS during_IN the_DT period_NN ._.
The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_VBN under_IN the_DT historical_JJ cost_NN convention_NN and_CC in_IN accordance_NN with_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC United_NNP Kingdom_NNP generally_RB accepted_VBD accounting_NN principles_NNS UK_NNP GAAP_NNP ._.
Where_WRB there_EX are_VBP significant_JJ differences_NNS to_TO United_NNP States_NNPS generally_RB accepted_VBN accounting_NN principles_NNS US_NNP GAAP_NNP these_DT have_VBP been_VBN discussed_VBN in_IN note_NN 29_CD ._.
Basis_NN of_IN consolidation_NN The_DT Group_NNP financial_JJ statements_NNS include_VBP and_CC consolidate_VBP the_DT financial_JJ statements_NNS of_IN Acambis_NNP plc_NN and_CC each_DT of_IN its_PRP$ subsidiary_NN undertakings_NNS ._.
Acquisitions_NNS made_VBN by_IN the_DT Group_NNP are_VBP accounted_VBN for_IN under_IN the_DT acquisition_NN method_NN of_IN accounting_NN and_CC the_DT Group_NNP financial_JJ statements_NNS include_VBP the_DT results_NNS of_IN such_JJ subsidiaries_NNS from_IN the_DT relevant_JJ date_NN of_IN acquisition_NN ._.
Intra-group_JJ transactions_NNS and_CC profits_NNS are_VBP eliminated_VBN fully_RB on_IN consolidation_NN ._.
The_DT loss_NN for_IN the_DT financial_JJ year_NN ,_, dealt_VBN with_IN in_IN the_DT financial_JJ statements_NNS of_IN the_DT Company_NN ,_, was_VBD 1.6_CD m_NN 2001_CD profit_NN of_IN 4.6_CD m._FW Under_IN the_DT provisions_NNS of_IN Section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, no_DT profit_NN and_CC loss_NN account_NN is_VBZ presented_VBN for_IN the_DT Company_NN ._.
Turnover_NN Group_NNP turnover_NN comprises_VBZ the_DT value_NN of_IN sales_NNS excluding_VBG VAT_NNP and_CC similar_JJ taxes_NNS ,_, trade_NN discounts_NNS and_CC intra-group_JJ transactions_NNS and_CC income_NN derived_VBN from_IN product_NN sales_NNS ,_, licence_NN fees_NNS ,_, contract_NN research_NN fees_NNS and_CC development_NN milestone_NN payments_NNS receivable_JJ from_IN third_JJ parties_NNS in_IN the_DT normal_JJ course_NN of_IN business_NN ._.
Revenue_NN from_IN product_NN sales_NNS is_VBZ recognized_VBN on_IN delivery_NN of_IN the_DT product_NN ._.
Non-refundable_JJ licence_NN fees_NNS are_VBP recognized_VBN over_IN the_DT term_NN of_IN the_DT licence_NN ._.
Where_WRB the_DT Group_NNP is_VBZ required_VBN to_TO undertake_VB research_NN and_CC development_NN activities_NNS and_CC the_DT fee_NN is_VBZ creditable_JJ against_IN services_NNS provided_VBN by_IN the_DT Group_NNP ,_, that_IN licence_NN fee_NN is_VBZ deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN over_IN which_WDT the_DT services_NNS are_VBP performed_VBN ._.
Contract_NN research_NN fees_NNS are_VBP recognized_VBN in_IN the_DT accounting_NN period_NN in_IN which_WDT the_DT related_JJ work_NN is_VBZ carried_VBN out_RP ._.
Access_NN fees_NNS and_CC milestones_NNS receivable_NN are_VBP recognized_VBN when_WRB they_PRP fall_VBP contractually_RB due_JJ ._.
Profit_NN is_VBZ recognized_VBN on_IN long-term_JJ contracts_NNS when_WRB the_DT final_JJ outcome_NN can_MD be_VB assessed_VBN with_IN reasonable_JJ certainty_NN by_IN including_VBG in_IN the_DT profit_NN and_CC loss_NN account_NN ,_, turnover_NN and_CC related_JJ costs_NNS as_IN contract_NN activity_NN progresses_VBZ ._.
Turnover_NN is_VBZ recognized_VBN according_VBG to_TO the_DT stage_NN reached_VBN in_IN the_DT contract_NN by_IN reference_NN to_TO the_DT costs_NNS incurred_VBN in_IN relation_NN to_TO total_JJ estimated_VBN expected_VBN costs_NNS ._.
The_DT second_JJ smallpox_NN vaccine_NN contract_NN with_IN the_DT US_NNP Centers_NNPS for_IN Disease_NNP Control_NNP &_CC Prevention_NNP CDC_NNP is_VBZ a_DT fixed_VBN fee_NN arrangement_NN requiring_VBG the_DT delivery_NN of_IN products_NNS as_RB well_RB as_IN a_DT concurrent_JJ research_NN and_CC development_NN R&D_NN program_NN ._.
This_DT arrangement_NN has_VBZ been_VBN treated_VBN as_IN a_DT single_JJ long-term_JJ contract_NN ,_, whose_WP$ elements_NNS have_VBP not_RB been_VBN accounted_VBN for_IN separately_RB ._.
Turnover_NN and_CC profits_NNS are_VBP recognized_VBN according_VBG to_TO the_DT stage_NN reached_VBN in_IN the_DT contract_NN ,_, as_IN described_VBN above_IN ._.
Manufacturing_NNP costs_NNS are_VBP deemed_VBN to_TO be_VB incurred_VBN on_IN delivery_NN of_IN products_NNS :_: R&D_NN costs_NNS are_VBP recognized_VBN as_IN incurred_VBN ._.
Cost_NN of_IN sales_NNS The_DT Group_NNP has_VBZ classified_VBN costs_NNS which_WDT are_VBP directly_RB attributable_JJ to_TO funded_JJ research_NN and_CC vaccine_NN manufacture_NN programs_NNS as_IN cost_NN of_IN sales_NNS ._.
Certain_JJ research_NN and_CC development_NN costs_NNS were_VBD ,_, in_IN prior_JJ years_NNS ,_, classified_VBN as_IN R&D_NNP expenditure_NN ._.
The_DT Directors_NNS believe_VBP that_IN the_DT new_JJ classification_NN more_RBR appropriately_RB reflects_VBZ the_DT nature_NN of_IN the_DT arrangements_NNS the_DT Group_NNP has_VBZ entered_VBN into_IN ._.
This_DT reclassification_NN has_VBZ been_VBN applied_VBN to_TO the_DT two_CD CDC_NNP smallpox_NN vaccine_NN contracts_NNS ._.
The_DT financial_JJ information_NN for_IN 2001_CD and_CC 2000_CD has_VBZ been_VBN re-presented_VBN so_RB that_IN cost_NN classifications_NNS are_VBP shown_VBN on_IN a_DT comparable_JJ basis_NN ._.
The_DT monetary_JJ impact_NN of_IN this_DT re-classification_NN in_IN 2001_CD and_CC 2000_CD is_VBZ 5.1_CD m_NN and_CC 0.5_CD m_NN respectively_RB ,_, which_WDT was_VBD previously_RB included_VBN within_IN R&D_NNP costs_NNS ._.
There_EX is_VBZ no_DT impact_NN on_IN net_JJ profit_NN ._.
Research_NNP and_CC development_NN R&D_NN costs_NNS are_VBP written_VBN off_RP in_IN the_DT period_NN in_IN which_WDT they_PRP are_VBP incurred_VBN ._.
THE_DT INFORMATION_NN CONTAINED_VBD IN_IN THIS_NNP COLUMN_NNP HAS_VBZ NOT_RB BEEN_JJ AUDITED_NN ._.
Government_NNP grants_NNS Grants_NNPS ,_, which_WDT are_VBP non-refundable_JJ ,_, are_VBP intended_VBN to_TO contribute_VB towards_IN specific_JJ costs_NNS and_CC are_VBP recognized_VBN in_IN line_NN with_IN the_DT proportion_NN of_IN those_DT costs_NNS incurred_VBN and_CC are_VBP netted_VBN off_RP against_IN R&D_NNP costs_NNS ._.
Pension_NN costs_NNS All_DT schemes_NNS are_VBP defined_VBN contribution_NN schemes_NNS and_CC pension_NN contributions_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN the_DT year_NN to_TO which_WDT they_PRP relate_VBP ._.
Any_DT difference_NN between_IN amounts_NNS charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN and_CC contributions_NNS paid_VBN are_VBP shown_VBN in_IN the_DT balance_NN sheet_NN under_IN prepayments_NNS or_CC creditors_NNS falling_VBG due_JJ within_IN one_CD year_NN ._.
Taxation_NNP Current_NNP tax_NN ,_, including_VBG UK_NNP corporation_NN tax_NN and_CC foreign_JJ tax_NN ,_, is_VBZ provided_VBN at_IN amounts_NNS expected_VBN to_TO be_VB paid_VBN or_CC recovered_VBN using_VBG the_DT tax_NN rates_NNS and_CC laws_NNS that_WDT have_VBP been_VBN enacted_VBN or_CC substantially_RB enacted_VBN by_IN the_DT balance_NN sheet_NN date_NN ._.
Provision_NNP is_VBZ made_VBN for_IN all_DT deferred_VBN tax_NN assets_NNS and_CC liabilities_NNS in_IN accordance_NN with_IN FRS_NNP 19_CD ,_, using_VBG full_JJ provision_NN accounting_NN ,_, when_WRB an_DT event_NN has_VBZ taken_VBN place_NN by_IN the_DT balance_NN sheet_NN date_NN which_WDT gives_VBZ rise_NN to_TO an_DT increased_VBN or_CC reduced_VBN tax_NN liability_NN in_IN the_DT future_NN ._.
Deferred_JJ tax_NN is_VBZ measured_VBN at_IN the_DT average_JJ tax_NN rates_NNS that_WDT are_VBP expected_VBN to_TO apply_VB in_IN the_DT periods_NNS in_IN which_WDT the_DT timing_NN differences_NNS are_VBP expected_VBN to_TO reverse_VB ,_, based_VBN on_IN tax_NN rates_NNS and_CC laws_NNS that_WDT have_VBP been_VBN enacted_VBN or_CC substantially_RB enacted_VBN by_IN the_DT balance_NN sheet_NN date_NN ._.
Deferred_JJ tax_NN assets_NNS are_VBP recognized_VBN to_TO the_DT extent_NN that_IN they_PRP are_VBP regarded_VBN as_IN recoverable_JJ ._.
Deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS are_VBP not_RB discounted_VBN ._.
Intangible_JJ assets_NNS goodwill_NN Goodwill_NNP arising_VBG on_IN the_DT acquisition_NN of_IN subsidiary_NN undertakings_NNS ,_, representing_VBG the_DT excess_NN of_IN fair_JJ value_NN of_IN the_DT consideration_NN given_VBN over_IN the_DT fair_JJ value_NN of_IN the_DT identified_VBN assets_NNS and_CC liabilities_NNS acquired_VBN ,_, is_VBZ capitalized_VBN and_CC written_VBN off_RP on_IN a_DT straight-line_JJ basis_NN over_IN its_PRP$ useful_JJ economic_JJ life_NN ._.
The_DT Directors_NNS are_VBP of_IN the_DT opinion_NN that_IN the_DT useful_JJ economic_JJ life_NN of_IN goodwill_NN will_MD not_RB exceed_VB 15_CD years_NNS ._.
The_DT carrying_VBG values_NNS of_IN goodwill_NN and_CC intangible_JJ assets_NNS are_VBP subject_JJ to_TO review_VB and_CC any_DT impairment_NN is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
Tangible_JJ fixed_JJ assets_NNS Fixed_VBN assets_NNS are_VBP stated_VBN at_IN original_JJ historical_JJ cost_NN ,_, net_NN of_IN depreciation_NN and_CC any_DT provision_NN for_IN impairment_NN ._.
Depreciation_NN is_VBZ provided_VBN on_IN all_DT tangible_JJ fixed_JJ assets_NNS at_IN rates_NNS calculated_VBN to_TO write_VB off_RP the_DT cost_NN of_IN each_DT asset_NN on_IN a_DT straight-line_JJ basis_NN over_IN its_PRP$ expected_VBN useful_JJ life_NN ,_, or_CC the_DT period_NN of_IN the_DT lease_NN if_IN shorter_JJR ,_, to_TO its_PRP$ residual_JJ value_NN based_VBN on_IN prices_NNS prevailing_VBG at_IN the_DT date_NN of_IN acquisition_NN ,_, as_IN follows_VBZ :_: Leasehold_VB land_NN and_CC buildings_NNS 15_CD years_NNS or_CC term_NN of_IN lease_NN if_IN shorter_JJR Laboratory_NN and_CC manufacturing_NN equipment_NN 4_CD to_TO 7_CD years_NNS Office_NNP equipment_NN 3_CD to_TO 5_CD years_NNS The_DT carrying_NN values_NNS of_IN tangible_JJ fixed_JJ assets_NNS are_VBP subject_JJ to_TO review_VB and_CC any_DT impairment_NN is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
The_DT Group_NNP does_VBZ not_RB capitalize_VB interest_NN charges_NNS on_IN loans_NNS to_TO fund_VB the_DT purchase_NN of_IN tangible_JJ fixed_JJ assets_NNS ._.
Investments_NNP Shares_NNP in_IN the_DT Company_NN purchased_VBD for_IN employee_NN share_NN options_NNS are_VBP held_VBN under_IN trust_NN and_CC are_VBP included_VBN as_IN a_DT fixed_JJ asset_NN investment_NN until_IN the_DT interest_NN in_IN the_DT shares_NNS is_VBZ unconditionally_RB transferred_VBN to_TO the_DT employees_NNS ._.
Provision_NNP is_VBZ made_VBN for_IN any_DT permanent_JJ impairment_NN in_IN the_DT value_NN of_IN the_DT shares_NNS held_VBN by_IN the_DT trust_NN ._.
The_DT Groups_NNS other_JJ fixed_VBN asset_NN investments_NNS are_VBP shown_VBN at_IN cost_NN less_JJR any_DT provision_NN for_IN impairment_NN ._.
Joint_NNP venture_NN undertakings_NNS Joint_NNP ventures_NNS are_VBP dealt_VBN with_IN under_IN the_DT gross_JJ equity_NN method_NN ._.
The_DT Groups_NNS share_NN of_IN revenues_NNS and_CC operating_NN losses_NNS for_IN the_DT joint_JJ venture_NN is_VBZ included_VBN in_IN the_DT Group_NNP profit_NN and_CC loss_NN account_NN and_CC the_DT Groups_NNS share_NN of_IN gross_JJ assets_NNS and_CC liabilities_NNS is_VBZ included_VBN in_IN the_DT Group_NNP balance_NN sheet_NN ._.
Short-term_JJ investments_NNS Bank_NNP deposits_NNS ,_, which_WDT are_VBP not_RB repayable_JJ on_IN demand_NN ,_, are_VBP treated_VBN as_IN short-term_JJ investments_NNS in_IN accordance_NN with_IN FRS_NNP 1_CD ,_, Cash_NN flow_NN statements_NNS ._.
Movements_NNS in_IN such_JJ investments_NNS are_VBP included_VBN under_IN management_NN of_IN liquid_JJ resources_NNS in_IN the_DT Groups_NNS cash_NN flow_NN statement_NN ._.
Stock_NNP ,_, excluding_VBG long-term_JJ contracts_NNS Stock_NNP is_VBZ stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
In_IN general_JJ ,_, cost_NN is_VBZ determined_VBN on_IN a_DT first-in-first-out_JJ basis_NN and_CC includes_VBZ transport_NN and_CC handling_VBG costs_NNS ._.
Where_WRB necessary_JJ ,_, provision_NN is_VBZ made_VBN for_IN obsolete_JJ ,_, slow-moving_JJ and_CC defective_JJ stock_NN ._.
23_CD 24_CD NOTES_NNS TO_TO GROUP_NNP FINANCIAL_NNP STATEMENTS_NNP 31_CD December_NNP 2002_CD Leases_NNP Assets_NNPS acquired_VBD under_IN finance_NN leases_NNS are_VBP included_VBN in_IN the_DT balance_NN sheet_NN as_IN tangible_JJ fixed_JJ assets_NNS and_CC are_VBP depreciated_VBN over_IN the_DT shorter_JJR of_IN the_DT lease_NN period_NN or_CC their_PRP$ useful_JJ Turnover_NN lives_NNS ._.
The_DT capital_NN elements_NNS of_IN future_JJ lease_NN payments_NNS are_VBP recorded_VBN as_IN liabilities_NNS ,_, while_IN the_DT interest_NN elements_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT period_NN of_IN Our_PRP$ turnover_NN represents_VBZ product_NN the_DT leases_NNS to_TO give_VB a_DT constant_JJ charge_NN on_IN the_DT balance_NN of_IN the_DT capital_NN repayments_NNS outstanding_JJ ._.
The_DT cost_NN of_IN operating_VBG leases_NNS is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN on_IN a_DT sales_NNS and_CC revenues_NNS for_IN research_NN and_CC straight-line_JJ basis_NN over_IN the_DT lease_NN term_NN ,_, even_RB if_IN rental_JJ payments_NNS are_VBP not_RB made_VBN on_IN such_PDT a_DT basis_NN ._.
Foreign_JJ currencies_NNS SOURCES_NNS OF_IN TURNOVER_NNP Transactions_NNS denominated_VBD in_IN foreign_JJ currencies_NNS are_VBP recorded_VBN in_IN the_DT local_JJ currency_NN at_IN actual_JJ exchange_NN rates_NNS as_RB at_IN the_DT date_NN of_IN the_DT transaction_NN ._.
Monetary_NNP assets_NNS and_CC liabilities_NNS denominated_VBN in_IN foreign_JJ currencies_NNS are_VBP translated_VBN at_IN the_DT rates_NNS ruling_VBG at_IN the_DT balance_NN sheet_NN date_NN ._.
Any_DT gain_NN or_CC loss_NN arising_VBG from_IN a_DT change_NN in_IN exchange_NN rates_NNS subsequent_JJ to_TO the_DT date_NN of_IN the_DT transaction_NN is_VBZ included_VBN as_IN an_DT exchange_NN gain_NN or_CC loss_NN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
Assets_NNS and_CC liabilities_NNS of_IN overseas_JJ subsidiary_NN and_CC joint_JJ venture_NN undertakings_NNS are_VBP translated_VBN into_IN sterling_NN at_IN rates_NNS of_IN exchange_NN ruling_NN at_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT results_NNS and_CC cash_NN flows_NNS of_IN overseas_JJ subsidiary_NN and_CC joint_JJ venture_NN undertakings_NNS are_VBP translated_VBN into_IN sterling_NN using_VBG average_JJ rates_NNS of_IN exchange_NN ._.
Exchange_NNP adjustments_NNS arising_VBG when_WRB the_DT opening_NN net_JJ assets_NNS and_CC the_DT losses_NNS for_IN the_DT year_NN retained_VBN by_IN overseas_JJ subsidiary_NN and_CC joint_JJ venture_NN undertakings_NNS are_VBP translated_VBN into_IN sterling_NN are_VBP taken_VBN directly_RB to_TO reserves_NNS and_CC reported_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ._.
Where_WRB financing_NN of_IN a_DT foreign_JJ subsidiary_NN through_IN long-term_JJ loans_NNS and_CC deferred_VBN trading_NN balances_NNS is_VBZ intended_VBN to_TO be_VB as_IN permanent_JJ as_IN equity_NN ,_, such_JJ loans_NNS and_CC inter-company_JJ balances_NNS are_VBP treated_VBN as_IN part_NN of_IN the_DT net_JJ investment_NN and_CC ,_, as_IN such_JJ ,_, any_DT exchange_NN differences_NNS arising_VBG are_VBP dealt_VBN with_IN as_IN adjustments_NNS to_TO reserves_NNS ._.
Financial_NNP instruments_NNS The_DT Group_NNP attempts_VBZ to_TO reduce_VB its_PRP$ foreign_JJ currency_NN exposure_NN using_VBG forward_RB planning_VBG of_IN currency_NN requirements_NNS for_IN US_NNP dollars_NNS and_CC UK_NNP sterling_NN ,_, and_CC entering_VBG into_IN spot_NN rate_NN currency_NN contracts_NNS as_IN appropriate_JJ ._.
The_DT Group_NNP does_VBZ not_RB enter_VB into_IN derivative_JJ transactions_NNS ._.
2000_CD 2001_CD Employee_NN share_NN option_NN schemes_NNS Other_JJ sources_NNS include_VBP revenues_NNS In_IN accordance_NN with_IN Urgent_NNP Issues_NNP Task_NNP Force_NNP UITF_NNP Abstract_NNP 17_CD ,_, Employee_NNP Share_NNP Schemes_NNP UITF_NNP 17_CD ,_, the_DT cost_NN of_IN awards_NNS to_TO employees_NNS of_IN share_NN options_NNS is_VBZ charged_VBN to_TO receivable_NN from_IN Aventis_NNP Pasteur_NNP for_IN the_DT profit_NN and_CC loss_NN account_NN on_IN a_DT straight-line_JJ basis_NN over_IN the_DT period_NN to_TO which_WDT the_DT performance_NN relates_VBZ ,_, based_VBN on_IN an_DT assessment_NN of_IN the_DT probability_NN of_IN the_DT performance_NN our_PRP$ ChimeriVax-Dengue_NNP project_NN and_CC criteria_NNS being_VBG met_VBN ._.
The_DT cost_NN of_IN such_JJ awards_NNS is_VBZ calculated_VBN as_IN the_DT difference_NN between_IN the_DT fair_JJ value_NN of_IN the_DT shares_NNS at_IN the_DT date_NN of_IN the_DT grant_NN and_CC the_DT exercise_NN price_NN of_IN the_DT our_PRP$ H._NN pylori_NN joint_JJ venture_NN ._.
Any_DT liability_NN relating_VBG to_TO National_NNP Insurance_NNP payments_NNS due_JJ on_IN exercise_NN of_IN options_NNS that_WDT has_VBZ not_RB been_VBN transferred_VBN to_TO the_DT employees_NNS is_VBZ also_RB accrued_VBN over_IN the_DT performance_NN period_NN of_IN the_DT option_NN ._.
2_CD Segmental_JJ information_NN Turnover_NN 4b_NN The_DT Groups_NNS turnover_NN comprises_VBZ product_NN sales_NNS ,_, licence_NN fees_NNS ,_, contract_NN research_NN fees_NNS ,_, royalties_NNS and_CC milestone_NN payments_NNS ._.
One_CD customer_NN ,_, the_DT CDC_NNP ,_, accounted_VBD for_IN 95_CD %_NN ,_, 64_CD %_NN and_CC 9_CD %_NN of_IN Group_NNP turnover_NN in_IN 2002_CD ,_, 2001_CD and_CC 2000_CD respectively_RB ._.
The_DT Directors_NNS are_VBP of_IN the_DT opinion_NN that_IN the_DT Group_NNP has_VBZ only_RB one_CD class_NN of_IN business_NN ._.
The_DT geographical_JJ analysis_NN of_IN turnover_NN by_IN origin_NN and_CC destination_NN ,_, operating_VBG profit_NN loss_NN and_CC net_JJ assets_NNS liabilities_NNS and_CC share_NN of_IN loss_NN of_IN the_DT joint_JJ venture_NN is_VBZ as_IN follows_VBZ :_: Europe_NNP North_NNP America_NNP 2002 2001 2000 2002_CD 2001 2000 000 000_CD 000 000 000 000_CD Turnover_NN by_IN customer_NN location_NN 785_CD 73_CD 265_CD 78,931_CD 8,841_CD 5,999_CD Turnover_NN by_IN origin_NN 785_CD 73_CD 265_CD 78,931_CD 8,841_CD 5,999_CD Profit_NN loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 2,741_CD 601_CD 5,942_CD 12,319_CD 13,159_CD 5,132_CD Net_JJ assets_NNS liabilities_NNS 53,537_CD 55,805_CD 35,377_CD 7,286_CD 28,145_CD 762_CD Share_NN of_IN loss_NN of_IN Joint_NNP Venture_NNP -_: --_: 171_CD 410_CD 2,138_CD In_IN 2002_CD ,_, sales_NNS to_TO Europe_NNP represented_VBD 1_CD %_NN and_CC sales_NNS to_TO North_NNP America_NNP represented_VBD 99_CD %_NN of_IN total_JJ sales_NNS ._.
The_DT figures_NNS shown_VBN on_IN the_DT face_NN of_IN the_DT Group_NNP profit_NN and_CC loss_NN account_NN on_IN page_NN 18_CD analyze_VBP the_DT operating_NN profit_NN loss_NN before_IN finance_NN charges_NNS and_CC taxation_NN ._.
The_DT net_JJ liabilities_NNS of_IN the_DT joint_JJ venture_NN with_IN Aventis_NNP Pasteur_NNP of_IN 0.2_CD m_NN 2001_CD net_JJ assets_NNS of_IN 0.1_CD m_NN ,_, see_VBP note_NN 14_CD d_SYM are_VBP included_VBN within_IN North_NNP America_NNP ._.
3_CD Administrative_JJ costs_NNS Amortisation_NNP of_IN goodwill_NN 2002 2001 2000_CD This_DT goodwill_NN arose_VBD when_WRB Acambis_NNP Inc._NNP 000 000 000_CD was_VBD acquired_VBN in_IN 1999_CD ._.
It_PRP is_VBZ being_VBG written_VBN Administrative_JJ costs_NNS 3,053_CD 2,295_CD 1,745_CD off_IN over_IN 15_CD years_NNS ,_, resulting_VBG in_IN an_DT annual_JJ Amortisation_NNP of_IN goodwill_NN 1,204_CD 1,204_CD 1,204_CD charge_NN to_TO the_DT profit_NN and_CC loss_NN account_NN of_IN 4,257_CD 3,499_CD 2,949_CD 1.2_CD m_NN see_VBP note_NN 12_CD ._.
4_CD Discontinued_VBN operations_NNS Interest_NN element_NN of_IN finance_NN leases_NNS During_IN 2000_CD ,_, the_DT Group_NNP completed_VBD the_DT disposal_NN of_IN its_PRP$ interest_NN in_IN its_PRP$ drug_NN discovery_NN business_NN ,_, Mimetrix_NNP ,_, to_TO Medivir_NNP AB_NNP ,_, a_DT Swedish_JJ biotechnology_NN company_NN listed_VBN on_IN the_DT During_IN 2001_CD ,_, the_DT Group_NNP put_VBD in_IN place_NN Stockholm_NNP Stock_NNP Exchange_NNP ._.
The_DT results_NNS of_IN Mimetrix_NNP up_IN to_TO 31_CD March_NNP 2000_CD the_DT date_NN from_IN which_WDT Medivir_NNP AB_NNP assumed_VBD the_DT obligations_NNS of_IN Mimetrixs_NNP operating_VBG activities_NNS a_DT $_$ 40_CD million_CD c._NN 25m_JJ lease-finance_NN are_VBP as_IN follows_VBZ :_: facility_NN to_TO fund_VB the_DT reactivation_NN of_IN our_PRP$ 2000_CD manufacturing_NN plant_NN ._.
The_DT repayment_NN 000_CD obligations_NNS for_IN the_DT lease_NN financing_NN Turnover_NN -_: are_VBP as_IN follows_VBZ :_: Research_NNP and_CC development_NN costs_NNS 643_CD Administrative_JJ costs_NNS 81_CD None_NN in_IN 2002_CD :_: Operating_NN loss_NN 724_CD Interest_NN only_RB in_IN 2003_CD :_: and_CC Capital_NNP and_CC interest_NN during_IN 2004_CD The_DT Mimetrix_NNP activities_NNS were_VBD all_DT UK-based_JJ ._.
Consequently_RB ,_, interest_NN that_WDT accrued_VBD 5_CD Amounts_NNS written_VBN off_RP fixed_VBN asset_NN investment_NN in_IN 2002_CD has_VBZ been_VBN added_VBN into_IN the_DT During_IN the_DT year_NN ,_, the_DT investment_NN of_IN shares_NNS held_VBN in_IN Medivir_NNP AB_NNP ,_, which_WDT were_VBD acquired_VBN in_IN 2000_CD in_IN exchange_NN for_IN the_DT assets_NNS of_IN Mimetrix_NNP Limited_NNP ,_, were_VBD written_VBN down_RP to_TO reflect_VB outstanding_JJ balance_NN ._.
the_DT fall_NN in_IN market_NN value_NN during_IN the_DT year_NN ._.
This_DT resulted_VBD in_IN an_DT exceptional_JJ loss_NN of_IN 0.1_CD m_NN 2001_CD 0.4_CD m._NN This_DT adjustment_NN was_VBD in_IN accordance_NN with_IN FRS_NNP 11_CD ,_, Impairment_NN of_IN Fixed_NNP Assets_NNPS and_CC Goodwill_NNP ._.
6_CD Interest_NN payable_JJ and_CC similar_JJ charges_NNS This_DT note_NN details_NNS the_DT interest_NN payable_JJ on_IN the_DT Arilvax_NNP overdraft_NN facility_NN see_VBP note_NN 18_CD for_IN more_JJR information_NN ,_, as_RB well_RB as_IN interest_NN from_IN assets_NNS held_VBN under_IN finance_NN leases_NNS ._.
2002 2001 2000 000_CD 000_CD 000_CD On_IN bank_NN overdrafts_NNS 93 214 211_CD Interest_NN element_NN of_IN finance_NN leases_NNS 1,118_CD -_: 5_CD 1,211_CD 214_CD 216_CD 7_CD Profit_NN loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN Profit_NN loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN is_VBZ stated_VBN :_: 2002 2001 2000_CD Notes_NNS 000 000 000_CD After_IN crediting_VBG :_: Grant_NNP income_NN 1,892_CD 1,142_CD 165_CD And_CC after_IN charging_VBG :_: Amortisation_NNP of_IN goodwill_NN 12_CD 1,204_CD 1,204_CD 1,204_CD Depreciation_NN of_IN tangible_JJ fixed_JJ assets_NNS 13_CD owned_VBN 1,148_CD 851_CD 855_CD held_VBN under_IN finance_NN leases_NNS 262_SYM -_: 73_CD Operating_NN lease_NN charges_NNS 26_CD a_DT hire_NN of_IN plant_NN and_CC machinery_NN 13_CD 5_CD 77_CD other_JJ 1,379_CD 1,582_CD 1,630_CD Auditors_NNS remuneration_JJ audit_NN services_NNS Company_NN :_: 3,000_CD 77_CD 58_CD 60_CD In_IN 2002_CD ,_, the_DT Group_NNP paid_VBD amounts_NNS to_TO the_DT auditors_NNS of_IN 0.1_CD m_NN to_TO Arthur_NNP Andersen_NNP 2001_CD 0.1_CD m_NN ,_, 2000_CD 0.1_CD m_NN and_CC 0.1_CD m_NN to_TO LLP_NNP in_IN respect_NN of_IN non-audit_JJ services_NNS primarily_RB tax_NN compliance_NN and_CC advisory_JJ services_NNS ._.
25_CD 26_CD NOTES_NNS TO_TO GROUP_NNP FINANCIAL_NNP STATEMENTS_NNP 31_CD December_NNP 2002_CD 8_CD Staff_NN costs_NNS The_DT average_JJ monthly_JJ number_NN of_IN employees_NNS during_IN the_DT year_NN including_VBG Executive_NNP Directors_NNS was_VBD :_: 6d_VB Employee_NN numbers_NNS UK_NNP US_NNP 2002 2001 2000_CD As_IN shown_VBN in_IN our_PRP$ graph_NN below_IN ,_, our_PRP$ Number_NNP Number_NNP Number_NNP Number_NNP Number_NNP average_JJ number_NN of_IN employees_NNS rose_VBD Research_NNP and_CC development_NN 30_CD 87_CD 117_CD 88_CD 71_CD Manufacturing_NNP -_: 63_CD 63_CD 12_CD -_: significantly_RB in_IN 2002_CD ,_, principally_RB Administration_NNP 23_CD 39_CD 62_CD 50_CD 35_CD as_IN a_DT result_NN of_IN reactivating_VBG the_DT 53 189 242 150_CD 106_CD manufacturing_NN facility_NN and_CC the_DT work_NN on_IN the_DT CDC_NNP smallpox_NN vaccine_NN The_DT Group_NNP had_VBD 291_CD employees_NNS at_IN 31_CD December_NNP 2002 2001 178_CD ._.
The_DT Company_NN had_VBD four_CD employees_NNS ,_, all_DT of_IN whom_WP were_VBD Directors_NNS ,_, at_IN 31_CD December_NNP 2002_CD 2001_CD three_CD ,_, contracts_NNS ._.
250_CD The_DT cost_NN to_TO the_DT Group_NNP of_IN paying_VBG its_PRP$ staff_NN was_VBD :_: 2002 2001 2000 200_CD 000 000 000_CD Wages_NNS and_CC salaries_NNS 11,341_CD 7,505_CD 4,862_CD Social_NNP security_NN costs_NNS 1,942_CD 1,008_CD 433_CD 150_CD Other_JJ pension_NN and_CC 401K_JJ costs_NNS see_VBP note_NN 26_CD c_NN 447 226 235_CD 13,730_CD 8,739_CD 5,530_CD 100_CD During_IN 2002_CD ,_, a_DT third-party_JJ company_NN paid_VBD a_DT share_NN of_IN the_DT Groups_NNS administrative_JJ costs_NNS ,_, including_VBG 0.3_CD m_NN 2001_CD 0.3_CD m_NN ,_, 2000_CD 0.2_CD m_NN for_IN staff_NN costs_NNS ._.
These_DT costs_NNS are_VBP included_VBN in_IN the_DT figures_NNS shown_VBN above_IN ._.
Research_NNP and_CC 50_CD development_NN 9_CD Directors_NNS remuneration_NN ,_, interests_NNS and_CC transactions_NNS Administration_NNP Full_NNP disclosure_NN of_IN Directors_NNS remuneration_NN ,_, interests_NNS and_CC transactions_NNS is_VBZ given_VBN in_IN the_DT auditable_JJ part_NN of_IN the_DT remuneration_NN report_NN ._.
Aggregate_JJ gains_NNS made_VBN by_IN Directors_NNS on_IN Manufacturing_NNP 0_CD the_DT exercise_NN of_IN share_NN options_NNS were_VBD 0.7_CD m_NN 2001_CD 0.7_CD m._FW 2000_CD 2001_CD 10_CD Taxation_NNP We_PRP estimate_VBP that_IN the_DT headcount_NN will_MD Tax_NNP is_VBZ charged_VBN annually_RB ,_, on_IN profits_NNS made_VBN ,_, in_IN the_DT country_NN where_WRB each_DT company_NN is_VBZ based_VBN ._.
increase_NN during_IN 2003_CD up_IN to_TO around_IN 325_CD ._.
Tax_NNP on_IN profit_NN on_IN ordinary_JJ activities_NNS Taxation_NNP 2002 2001 2000_CD Loss-making_JJ R&D_NNP companies_NNS 000 000 000_CD traditionally_RB generate_VB taxable_JJ losses_NNS UK_NNP corporation_NN tax_NN at_IN 30_CD %_NN 2001_CD 30_CD %_NN :_: 2000_CD 30_CD %_NN :_: 100_CD --_: Foreign_JJ taxation_NN 201_CD -_: -_: which_WDT can_MD ,_, in_IN future_NN ,_, be_VB offset_VBN Over_IN provision_NN in_IN respect_NN of_IN prior_JJ year_NN 98_CD 131_CD -_: against_IN trading_NN profits_NNS ._.
For_IN as_RB long_JJ 3_CD 131_CD -_: as_IN it_PRP remains_VBZ uncertain_JJ that_IN the_DT Group_NNP will_MD have_VB taxable_JJ profits_NNS against_IN which_WDT these_DT taxable_JJ losses_NNS can_MD be_VB offset_VBN ,_, a_DT deferred_JJ tax_NN asset_NN historic_JJ taxable_JJ losses_NNS is_VBZ not_RB recognized_VBN in_IN the_DT accounts_NNS ._.
2002_CD has_VBZ seen_VBN a_DT small_JJ tax_NN charge_NN due_JJ to_TO state_NN taxation_NN liability_NN arising_VBG in_IN the_DT US_NNP which_WDT is_VBZ largely_RB offset_VBN by_IN an_DT R&D_NNP tax_NN credit_NN claimed_VBN in_IN the_DT UK_NNP ._.
Current_JJ taxation_NN The_DT tax_NN assessed_VBN for_IN the_DT year_NN is_VBZ different_JJ from_IN the_DT standard_JJ rate_NN of_IN corporation_NN tax_NN in_IN the_DT UK_NNP of_IN 30_CD %_NN ._.
The_DT differences_NNS are_VBP explained_VBN below_IN :_: 2002 2001 2000 000_CD 000_CD 000_CD Profit_NN loss_NN on_IN ordinary_JJ activities_NNS before_IN tax_NN 9,578_CD 12,558_CD 11,074_CD Profit_NN loss_NN on_IN ordinary_JJ activities_NNS multiplied_VBN by_IN the_DT standard_JJ rate_NN of_IN corporation_NN tax_NN in_IN the_DT UK_NNP of_IN 30_CD %_NN 2001_CD and_CC 2000_CD :_: R&D_NNP tax_NN credit_NN rate_NN of_IN 16_CD %_NN 2,873_CD 2,009_CD 1,772_CD Effects_NNPS of_IN :_: Utilisation_NN of_IN tax_NN losses_NNS 7,122_CD --_: Expenses_NNS not_RB deductible_JJ for_IN tax_NN purposes_NNS 663_CD 10_CD 58_CD Losses_NNS arising_VBG in_IN the_DT year_NN 548_CD 1,869_CD 1,831_CD Difference_NN in_IN tax_NN rates_NNS used_VBD compared_VBN to_TO UK_NNP standard_JJ rate_NN 664_CD --_: Difference_NN between_IN capital_NN allowances_NNS and_CC depreciation_NN 143_CD --_: Prior_RB year_NN R&D_NNP tax_NN credit_NN 98_CD --_: Other_JJ short-term_JJ timing_NN differences_NNS 2,618_CD 1_CD 1_CD Current_JJ tax_NN charge_NN credit_NN for_IN year_NN 3_CD 131_CD -_: Deferred_JJ tax_NN 2002 2001 000 000_CD Unrecognised_JJ asset_NN in_IN respect_NN of_IN accelerated_JJ capital_NN allowances_NNS 274_CD 450_CD Unrecognised_JJ tax_NN losses_NNS 8,535_CD 14,020_CD Unrecognised_JJ asset_NN on_IN short-term_JJ timing_NN differences_NNS 3,966_CD 1,515_CD Total_JJ unrecognised_JJ deferred_JJ tax_NN asset_NN 12,775_CD 15,985_CD 11_CD Earnings_NNS per_IN ordinary_JJ share_NN Basic_JJ earnings_NNS per_IN share_NN is_VBZ calculated_VBN by_IN dividing_VBG the_DT earnings_NNS attributable_JJ to_TO ordinary_JJ shareholders_NNS by_IN the_DT weighted_JJ average_JJ number_NN of_IN ordinary_JJ shares_NNS in_IN issue_NN during_IN the_DT year_NN ,_, excluding_VBG those_DT held_VBN in_IN the_DT employee_NN share_NN trust_NN see_VBP note_NN 14_CD c_NN which_WDT are_VBP treated_VBN as_IN canceled_VBN until_IN the_DT shares_NNS vest_NN unconditionally_RB with_IN the_DT employees_NNS ._.
For_IN diluted_VBN earnings_NNS per_IN share_NN ,_, the_DT weighted_JJ average_JJ numbers_NNS of_IN shares_NNS used_VBN in_IN the_DT calculations_NNS are_VBP set_VBN out_RP below_IN :_: 2002 2001 2000_CD Earnings_NNS Weighted_VBN average_JJ Per-share_JJ amount_NN Earnings_NNS Weighted_VBN average_JJ Per-share_JJ amount_NN Earnings_NNS Weighted_VBN average_JJ Per-share_JJ amount_NN 000_CD number_NN of_IN shares_NNS pence_NN 000_CD number_NN of_IN shares_NNS pence_NN 000_CD number_NN of_IN shares_NNS pence_NN Basic_JJ EPS_NNP Earnings_NNS attributable_JJ to_TO ordinary_JJ shareholders_NNS 9,57596,101,507_CD 10.0_CD 12,427_CD 91,027,463_CD 13.7_CD 11,074_CD 79,638,484_CD 13.9_CD Effect_NN of_IN dilutive_JJ securities_NNS Options_NNS -_: 2,875,375_CD 0.3_CD --_: -_: -_: -_: -_: Diluted_NNP EPS_NNP Adjusted_JJ earnings_NNS 9,57598,976,882_CD 9.7_CD 12,427_CD 91,027,463_CD 13.7_CD 11,074_CD 79,638,484_CD 13.9_CD For_IN diluted_VBN earnings_NNS per_IN share_NN ,_, the_DT weighted_JJ average_JJ ordinary_JJ shares_NNS in_IN issue_NN is_VBZ adjusted_VBN to_TO assume_VB conversion_NN of_IN all_DT dilutive_JJ potential_JJ ordinary_JJ shares_NNS ._.
The_DT Groups_NNS dilutive_JJ securities_NNS consist_VBP of_IN :_: those_DT share_NN options_NNS without_IN performance_NN conditions_NNS granted_VBN to_TO employees_NNS where_WRB the_DT exercise_NN price_NN is_VBZ less_JJR than_IN the_DT average_JJ market_NN price_NN of_IN the_DT Companys_NNP ordinary_JJ shares_NNS during_IN the_DT year_NN ,_, and_CC those_DT share_NN options_NNS with_IN performance_NN criteria_NNS and_CC contingently_RB issuable_JJ shares_NNS ,_, which_WDT are_VBP included_VBN in_IN the_DT diluted_JJ earnings_NNS per_IN share_NN calculation_NN where_WRB the_DT related_JJ performance_NN conditions_NNS have_VBP been_VBN met_VBN at_IN the_DT year-end_NN ._.
12_CD Goodwill_NNP This_DT goodwill_NN arose_VBD when_WRB Acambis_NNP Inc._NNP was_VBD acquired_VBN in_IN 1999_CD ._.
It_PRP is_VBZ being_VBG written_VBN off_RP over_IN 15_CD years_NNS ,_, resulting_VBG in_IN an_DT annual_JJ charge_NN to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
2002 2001 000 000_CD Cost_NN at_IN 1_CD January_NNP and_CC 31_CD December_NNP 18,055_CD 18,055_CD Amortisation_NNP At_IN 1_CD January_NNP 3,210_CD 2,006_CD Charge_NNP for_IN the_DT year_NN 1,204_CD 1,204_CD At_IN 31_CD December_NNP 4,414_CD 3,210_CD Net_JJ book_NN value_NN At_IN 31_CD December_NNP 13,641_CD 14,845_CD 27_CD 28_CD NOTES_NNS TO_TO GROUP_NNP FINANCIAL_NNP STATEMENTS_NNP 31_CD December_NNP 2002_CD 13_CD Tangible_JJ fixed_JJ assets_NNS Physical_JJ assets_NNS held_VBN for_IN continuing_VBG use_NN in_IN the_DT business_NN ._.
Exchange_NNP movement_NN Laboratory_NN and_CC During_IN 2002_CD ,_, the_DT monthly_JJ closing_NN Short_JJ leasehold_NN manufacturing_VBG Office_NNP land_NN and_CC buildings_NNS equipment_NN equipment_NN Total_JJ US_NNP $_$ exchange_NN rate_NN has_VBZ varied_VBN Group_NNP 000 000 000 000_CD between_IN 1.4555_CD and_CC 1.6095_CD ._.
This_DT Cost_NN has_VBZ given_VBN rise_NN to_TO an_DT exchange_NN rate_NN At_IN 1_CD January_NNP 2002_CD 10,111_CD 3,859_CD 869_CD 14,839_CD movement_NN on_IN the_DT assets_NNS located_VBN Additions_NNS 4,963_CD 4,519_CD 1,246_CD 10,728_CD in_IN the_DT US_NNP ,_, which_WDT has_VBZ an_DT impact_NN on_IN Disposals_NNS -_: 31 281 312_CD both_DT asset_NN cost_NN and_CC accumulated_VBN Exchange_NNP movement_NN 1,170_CD 765_CD 126_CD 2,061_CD depreciation_NN ._.
At_IN 31_CD December_NNP 2002_CD 13,904_CD 7,582_CD 1,708_CD 23,194_CD Depreciation_NN At_IN 1_CD January_NNP 2002_CD 1,274_CD 829_CD 481_CD 2,584_CD Subsidiary_NNP undertakings_NNS Charge_NNP for_IN year_NN 482 651 277_CD 1,410_CD The_DT principal_NN trading_NN subsidiaries_NNS Disposals_NNS -_: 22 281 303_CD of_IN the_DT Group_NNP are_VBP Acambis_NNP Research_NNP Exchange_NNP movement_NN 190_CD 250_CD 45_CD 485_CD Limited_NNP and_CC Acambis_NNP Inc._NNP ._.
The_DT At_IN 31_CD December_NNP 2002_CD 1,566_CD 1,208_CD 432_CD 3,206_CD Net_JJ book_NN value_NN structure_NN of_IN the_DT principal_JJ trading_NN At_IN 1_CD January_NNP 2002_CD 8,837_CD 3,030_CD 388_CD 12,255_CD subsidiaries_NNS of_IN the_DT Group_NNP is_VBZ as_IN At_IN 31_CD December_NNP 2002_CD 12,338_CD 6,374_CD 1,276_CD 19,988_CD follows_VBZ :_: Net_JJ book_NN value_NN of_IN assets_NNS held_VBN under_IN finance_NN lease_NN included_VBD above_IN :_: At_IN 1_CD January_NNP 2002_CD 5,220_CD 2,208_CD -_: 7,428_CD Acambis_NNP plc_NN At_IN 31_CD December_NNP 2002_CD 4,633_CD 1,923_CD -_: 6,556_CD The_DT Company_NN has_VBZ no_DT tangible_JJ fixed_JJ assets_NNS ._.
100_CD %_NN 100_CD %_NN Acambis_NNP Research_NNP Acambis_NNP Inc._NNP 14_CD Fixed_NNP asset_NN investments_NNS Limited_JJ These_DT are_VBP assets_NNS including_VBG shares_NNS that_WDT are_VBP held_VBN as_IN an_DT ongoing_JJ investment_NN ._.
Group_NNP Company_NNP 2002 2001 2002 2001_CD 000 000 000 000_CD a_DT Subsidiary_NNP undertakings_NNS -_: -_: 14,988_CD 14,988_CD b_NN Trade_NNP investments_NNS 303_CD 388_CD -_: -_: c_NN Investment_NN in_IN own_JJ shares_NNS 797_CD 1,252_CD 143_CD 598_CD 1,100_CD 1,640_CD 15,131_CD 15,586_CD d_SYM Joint_NNP venture_NN 206_CD 67_CD -_: -_: a_DT Subsidiary_NNP undertakings_NNS The_DT Company_NN ,_, Acambis_NNP plc_NN ,_, owns_VBZ 100_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN of_IN Acambis_NNP Research_NNP Limited_NNP and_CC Acambis_NNP Inc._NNP incorporated_VBN in_IN England_NNP and_CC Wales_NNP and_CC the_DT US_NNP 4c_CD respectively_RB ._.
The_DT main_JJ activity_NN of_IN Acambis_NNP Research_NNP Limited_NNP is_VBZ R&D_NNP ._.
The_DT main_JJ activities_NNS of_IN Acambis_NNP Inc._NNP are_VBP R&D_NNP and_CC manufacturing_NN ._.
Other_JJ companies_NNS held_VBN are_VBP not_RB significant_JJ to_TO the_DT Group_NNP ._.
All_DT subsidiary_NN undertakings_NNS have_VBP been_VBN consolidated_VBN ._.
The_DT cost_NN of_IN the_DT investments_NNS in_IN the_DT subsidiary_NN undertakings_NNS in_IN the_DT books_NNS of_IN the_DT Company_NN is_VBZ as_IN follows_VBZ :_: 000_CD Cost_NN and_CC net_JJ book_NN value_NN at_IN 1_CD January_NNP and_CC 31_CD December_NNP 2002_CD 14,988_CD THE_DT INFORMATION_NN CONTAINED_VBD IN_IN THIS_NNP COLUMN_NNP HAS_VBZ NOT_RB BEEN_JJ AUDITED_NN ._.
b_NN Trade_NNP investments_NNS Joint_NNP ventures_NNS The_DT investments_NNS held_VBN during_IN 2002_CD are_VBP shares_NNS the_DT Group_NNP holds_VBZ in_IN a_DT non-related_JJ overseas_JJ listed_VBN company_NN ,_, Medivir_NNP AB_NNP ._.
The_DT structure_NN of_IN the_DT H._NNP pylori_NN joint_JJ venture_NN is_VBZ shown_VBN in_IN the_DT following_VBG 2002_CD 2001_CD diagram_NN :_: 000_CD 000_CD Cost_NN At_IN 1_CD January_NNP 1,481_CD 1,481_CD Acambis_NNP Aventis_NNP Pasteur_NNP At_IN 31_CD December_NNP 1,481_CD 1,481_CD Amounts_NNS provided_VBN 50_CD %_NN 50_CD %_NN At_IN 1_CD January_NNP 1,093_CD 670_CD Provided_VBN in_IN the_DT year_NN 85_CD 423_CD Pasteur_NNP MrieuxAt_NNP 31_CD December_NNP 1,178_CD 1,093_CD OraVax_NNP joint_JJ venture_NN Net_NN book_NN value_NN At_IN 1_CD January_NNP 388_CD 811_CD 50.1_CD %_NN 49.9_CD %_NN At_IN 31_CD December_NNP 303_CD 388_CD Mrieux-OraVax_NNP SNC_NNP OraVax-Mrieux_NNP Co._NNP ._.
The_DT market_NN value_NN of_IN the_DT investment_NN in_IN Medivir_NNP AB_NNP at_IN 31_CD December_NNP 2002_CD was_VBD 0.3_CD m_NN 2001_CD 0.4_CD m._NN Through_IN the_DT Pasteur_NNP Mrieux-OraVax_NNP c_NN Investment_NN in_IN own_JJ shares_NNS joint_JJ venture_NN ,_, Acambis_NNP owns_VBZ 50.1_CD %_NN These_DT are_VBP shares_NNS in_IN Acambis_NNP plc_NN that_WDT have_VBP been_VBN bought_VBN by_IN an_DT employee_NN trust_NN ._.
The_DT shares_NNS may_MD be_VB issued_VBN to_TO certain_JJ employees_NNS and_CC Directors_NNS as_IN share_NN options_NNS or_CC of_IN Mrieux-OraVax_NNP SNC_NNP ,_, a_DT French_JJ long-term_JJ incentive_NN awards_NNS are_VBP exercised_VBN ._.
Provision_NNP has_VBZ been_VBN made_VBN for_IN those_DT shares_NNS that_WDT are_VBP likely_JJ to_TO be_VB issued_VBN ._.
partnership_NN ,_, and_CC 49.9_CD %_NN of_IN OraVaxMrieux_NNP Co._NNP a_DT Massachusetts_NNP General_NNP Group_NNP Company_NNP partnership_NN ._.
Aventis_NNP Pasteur_NNP owns_VBZ 2002 2001 2002 2001_CD 000 000 000 000_CD the_DT remaining_VBG balances_NNS of_IN the_DT Cost_NN two_CD partnerships_NNS ._.
At_IN 1_CD January_NNP 1,606_CD 1,606_CD 952_CD 952_CD Disposals_NNS 287_CD -_: 287_CD -_: Whilst_NNP Acambis_NNP and_CC Aventis_NNP Pasteurs_NNP At_IN 31_CD December_NNP 1,319_CD 1,606_CD 665_CD 952_CD interests_NNS in_IN each_DT of_IN the_DT partnerships_NNS Amounts_VBZ provided_VBN are_VBP very_RB slightly_RB different_JJ ,_, the_DT At_IN 1_CD January_NNP 354 161 354 161_CD collaboration_NN is_VBZ structured_VBN such_JJ that_IN Provided_VBN in_IN the_DT year_NN 420 193 420 193_CD all_DT costs_NNS ,_, capital_NN contributions_NNS ,_, profits_NNS Release_VBP of_IN previously_RB provided_VBN amounts_NNS 252_CD -_: 252_CD -_: and_CC losses_NNS are_VBP shared_VBN equally_RB by_IN At_IN 31_CD December_NNP 522 354 522 354_CD the_DT parties_NNS ._.
Net_JJ book_NN value_NN At_IN 1_CD January_NNP 1,252_CD 1,445_CD 598_CD 791_CD At_IN 31_CD December_NNP 797_CD 1,252_CD 143_CD 598_CD At_IN 31_CD December_NNP 2002_CD ,_, Acambis_NNP Employees_NNP Trustees_NNP Limited_NNP held_VBD 589,685_CD 2001_CD 723,396_CD ordinary_JJ shares_NNS in_IN the_DT Company_NN with_IN a_DT total_JJ market_NN value_NN of_IN 1.6_CD m_NN 2001_CD 2.5_CD m_NN on_IN behalf_NN of_IN the_DT Acambis_NNP Employees_NNP Trust_NNP ._.
All_DT shares_NNS held_VBN by_IN the_DT Trust_NNP have_VBP been_VBN allocated_VBN to_TO long-term_JJ incentive_NN awards_NNS and_CC a_DT provision_NN has_VBZ been_VBN made_VBN in_IN respect_NN of_IN all_DT of_IN these_DT shares_NNS ._.
All_DT costs_NNS relating_VBG to_TO the_DT administration_NN of_IN the_DT Trust_NNP are_VBP dealt_VBN with_IN in_IN the_DT accounts_NNS of_IN the_DT Company_NN as_IN they_PRP arise_VBP ._.
Disposals_NNS of_IN 0.3_CD m_NN 2001_CD nil_NN during_IN the_DT year_NN relate_VBP to_TO share_VB options_NNS granted_VBN in_IN accordance_NN with_IN the_DT rules_NNS of_IN the_DT Acambis_NNP Share_NN Incentive_NNP Plan_NNP LTIP_NNP having_VBG vested_VBN as_IN a_DT result_NN of_IN the_DT performance_NN criteria_NNS having_VBG been_VBN met_VBN at_IN the_DT exercise_NN date_NN ._.
During_IN the_DT year_NN ,_, a_DT provision_NN of_IN 0.4_CD m_NN 2001_CD 0.2_CD m_NN was_VBD made_VBN in_IN relation_NN to_TO share_VB options_NNS that_WDT have_VBP been_VBN granted_VBN in_IN accordance_NN with_IN the_DT rules_NNS of_IN the_DT LTIP_NNP ,_, as_IN a_DT result_NN of_IN the_DT performance_NN criteria_NNS having_VBG been_VBN met_VBN at_IN 31_CD December_NNP 2002_CD ._.
As_IN a_DT result_NN of_IN certain_JJ share_NN options_NNS becoming_VBG exercisable_JJ during_IN the_DT year_NN ,_, this_DT gave_VBD rise_NN to_TO a_DT release_NN of_IN 0.3_CD m_NN 2001_CD nil_NN being_VBG provisions_NNS made_VBN in_IN previous_JJ years_NNS see_VBP remuneration_JJ report_NN on_IN page_NN 62_CD for_IN further_JJ details_NNS ._.
d_LS Joint_NNP ventures_NNS The_DT Group_NNP has_VBZ an_DT interest_NN in_IN the_DT Pasteur_NNP Mrieux-OraVax_NNP joint_JJ venture_NN Joint_NNP Venture_NNP ,_, whose_WP$ principal_JJ business_NN is_VBZ to_TO develop_VB ,_, manufacture_VB ,_, market_NN and_CC sell_VB immunotherapeutic_JJ and_CC preventative_JJ vaccines_NNS against_IN H._NNP pylori_NN infection_NN in_IN humans_NNS ._.
The_DT Joint_NNP Venture_NNP represents_VBZ a_DT collaboration_NN between_IN two_CD partnerships_NNS ,_, MrieuxOraVax_NNP SNC_NNP and_CC OraVax-Mrieux_NNP Co._NNP incorporated_VBN in_IN Delaware_NNP ,_, US_NNP ._.
These_DT partnerships_NNS were_VBD formed_VBN in_IN March_NNP 1995_CD between_IN Acambis_NNP Inc._NNP and_CC Aventis_NNP Pasteur_NNP ._.
The_DT Joint_NNP Venture_NNP trades_VBZ under_IN the_DT name_NN of_IN Pasteur_NNP Mrieux-OraVax_NNP and_CC its_PRP$ accounting_NN year-end_NN is_VBZ 31_CD December_NNP ._.
The_DT R&D_NNP budgets_NNS of_IN the_DT two_CD partnerships_NNS are_VBP established_VBN by_IN joint_JJ committees_NNS in_IN which_WDT each_DT of_IN the_DT parties_NNS has_VBZ an_DT equal_JJ participation_NN and_CC role_NN ._.
The_DT parties_NNS pay_VBP approximately_RB equal_JJ shares_NNS of_IN the_DT agreed_VBN budgets_NNS ._.
29_CD 30_CD NOTES_NNS TO_TO GROUP_NNP FINANCIAL_NNP STATEMENTS_NNP 31_CD December_NNP 2002_CD 14_CD Fixed_VBN asset_NN investments_NNS d_LS Joint_NNP ventures_NNS continued_VBD Stock_NNP The_NNP following_VBG information_NN is_VBZ given_VBN in_IN respect_NN of_IN the_DT Groups_NNS share_NN of_IN the_DT Joint_NNP Venture_NNP :_: Stock_NNP is_VBZ a_DT new_JJ category_NN on_IN the_DT balance_NN sheet_NN and_CC consists_VBZ solely_RB of_IN 2002 2001 000 000_CD stock_NN relating_VBG to_TO the_DT production_NN of_IN smallpox_NN vaccine_NN ._.
Loss_NN before_IN tax_NN 171_CD 410_CD Current_JJ assets_NNS 941_CD 915_CD Trade_NNP debtors_NNS Liabilities_NNS due_JJ within_IN one_CD year_NN 1,147_CD 848_CD Amounts_NNS owed_VBN by_IN the_DT CDC_NNP under_IN the_DT 206_CD 67_CD two_CD smallpox_NN vaccine_NN contracts_NNS are_VBP included_VBN within_IN trade_NN debtors_NNS at_IN the_DT Due_JJ to_TO the_DT nature_NN of_IN this_DT Joint_NNP Venture_NNP ,_, being_VBG a_DT collaboration_NN between_IN two_CD partnerships_NNS ,_, the_DT following_VBG table_NN provides_VBZ an_DT alternative_JJ analysis_NN of_IN the_DT amounts_NNS shown_VBN above_IN :_: year-end_NN ._.
2002_CD 2001_CD Corporation_NNP tax_NN 000_CD 000_CD See_VB note_NN 10_CD on_IN pages_NNS 26_CD and_CC 27_CD Share_NN of_IN cumulative_JJ amounts_NNS invested_VBN in_IN the_DT partnerships_NNS 18,169_CD 20,090_CD for_IN details_NNS of_IN the_DT corporation_NN Share_NN of_IN cumulative_JJ losses_NNS incurred_VBN by_IN the_DT partnerships_NNS 18,375_CD 20,023_CD tax_NN calculation_NN ._.
206_CD 67_CD Stock_NNP 15_CD Group_NNP Company_NNP 2002 2001 2002 2001_CD 000 000 000 000_CD Raw_NNP materials_NNS 1,131_CD -_: -_: -_: Work_NN in_IN progress_NN 34,934_CD -_: -_: -_: Finished_VBN goods_NNS 12,278_CD -_: -_: -_: 48,343_SYM -_: -_: -_: 16_CD Debtors_NNS :_: amounts_NNS receivable_NN within_IN one_CD year_NN Group_NNP Company_NNP 2002 2001 2002 2001_CD 000 000 000 000_CD Trade_NNP debtors_NNS 46,090_CD 5,918_CD -_: -_: Other_JJ debtors_NNS 2,406_CD 285_CD 589_CD 42_CD Corporation_NNP tax_NN 198_CD 131_CD -_: -_: Prepayments_NNS and_CC accrued_VBN income_NN 5,346_CD 1,208_CD -_: 28_CD 54,040_CD 7,542_CD 589_CD 70_CD Debtors_NNS :_: amounts_NNS receivable_NN after_IN one_CD year_NN 17_CD Group_NNP Company_NNP 2002 2001 2002 2001_CD 000 000 000 000_CD Amounts_NNS owed_VBN by_IN subsidiary_NN undertakings_NNS -_: -_: 71,643_CD 60,170_CD Prepayments_NNS and_CC accrued_VBN income_NN 4,925_CD 6,235_CD -_: -_: 4,925_CD 6,235_CD 71,643_CD 60,170_CD Acambis_NNP is_VBZ required_VBN to_TO prepay_VB insurance_NN premiums_NNS ,_, on_IN behalf_NN of_IN the_DT CDC_NNP ,_, relating_VBG to_TO the_DT first_JJ CDC_NNP smallpox_NN vaccine_NN contract_NN ,_, secured_VBN in_IN September_NNP 2000_CD ._.
At_IN 31_CD December_NNP 2002_CD ,_, the_DT total_JJ amount_NN prepaid_VBN was_VBD 5.6_CD m_NN 2001_CD 7.0_CD m_NN ,_, of_IN which_WDT 0.7_CD m_NN 2001_CD 0.8_CD m_NN is_VBZ included_VBN within_IN Debtors_NNS :_: amounts_NNS receivable_NN within_IN one_CD year_NN and_CC 4.9_CD m_NN 2001_CD 6.2_CD m_NN is_VBZ included_VBN within_IN Debtors_NNS :_: amounts_NNS receivable_NN after_IN one_CD year_NN ._.
The_DT total_NN of_IN 5.6_CD m_NN 2001_CD 7.0_CD m_NN is_VBZ offset_VBN by_IN an_DT equal_JJ amount_NN in_IN creditors_NNS see_VBP THE_DT INFORMATION_NN CONTAINED_VBD IN_IN THIS_NNP COLUMN_NNP notes_VBZ 18_CD and_CC 19_CD ._.
Both_DT balances_NNS will_MD reduce_VB over_IN the_DT term_NN of_IN the_DT insurance_NN cover_NN ,_, which_WDT was_VBD up_RB to_TO 20_CD years_NNS at_IN inception_NN in_IN 2000_CD ._.
18_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN Group_NNP Company_NNP Trade_NNP creditors_NNS 2002 2001 2002 2001_CD This_DT includes_VBZ amounts_NNS payable_JJ to_TO 000 000 000 000_CD suppliers_NNS ,_, largely_RB for_IN payments_NNS Overdraft_NNP facility_NN see_VBP below_IN 4,349_CD 4,809_CD -_: -_: of_IN stock_NN ._.
Trade_NNP creditors_NNS 54,769_CD 3,674_CD 58_CD 47_CD Amounts_NNS owed_VBN to_TO Joint_NNP Venture_NNP -_: 496_CD -_: -_: Accruals_NNP and_CC deferred_JJ income_NN Corporation_NNP tax_NN 201_CD -_: -_: -_: Deferred_JJ income_NN represents_VBZ the_DT Other_JJ taxes_NNS and_CC social_JJ security_NN 87_CD 69_CD -_: -_: difference_NN between_IN invoices_NNS Other_JJ creditors_NNS 58_CD 44_CD 49_CD -_: submitted_VBN to_TO the_DT CDC_NNP before_IN the_DT Accruals_NNP and_CC deferred_JJ income_NN 28,996_CD 7,511_CD 322_CD 172_CD year-end_NN and_CC amounts_VBZ recognized_VBN 88,460_CD 16,603_CD 429_CD 219_CD as_IN revenue_NN ._.
Under_IN the_DT terms_NNS of_IN the_DT agreement_NN between_IN Acambis_NNP and_CC Evans_NNP Vaccines_NNP Limited_NNP ,_, given_VBN certain_JJ conditions_NNS ,_, the_DT obligation_NN under_IN the_DT bank_NN overdraft_NN facility_NN of_IN 4.3_CD m_NN 2001_CD 4.8_CD m_NN for_IN the_DT costs_NNS incurred_VBN on_IN the_DT Arilvax_NNP project_NN may_MD be_VB repayable_JJ within_IN one_CD year_NN ._.
The_DT facility_NN is_VBZ underwritten_VBN by_IN PowderJect_NNP Pharmaceuticals_NNP Plc_NNP PowderJect_NNP ._.
PowderJect_NNP has_VBZ granted_VBN to_TO Acambis_NNP 100_CD %_NN of_IN the_DT marketing_NN rights_NNS to_TO Arilvax_NNP in_IN the_DT US_NNP ,_, whilst_NN retaining_VBG an_DT option_NN to_TO buy_VB back_RB 50_CD %_NN of_IN the_DT profits_NNS from_IN the_DT US_NNP sales_NNS in_IN return_NN for_IN refunding_VBG to_TO the_DT Group_NNP the_DT costs_NNS the_DT Group_NNP has_VBZ incurred_VBN on_IN the_DT Arilvax_NNP program_NN ._.
The_DT overdraft_NN facility_NN was_VBD renewed_VBN in_IN January_NNP 2003_CD for_IN a_DT further_JJ year_NN ._.
Interest_NN is_VBZ charged_VBN as_RB disclosed_VBN within_IN Financial_NNP liabilities_NNS in_IN note_NN 20_CD ._.
During_IN the_DT year_NN an_DT exchange_NN gain_NN of_IN 0.4_CD m_NN 2001_CD exchange_NN loss_NN of_IN 0.1_CD m_NN was_VBD recorded_VBN on_IN the_DT face_NN of_IN the_DT Group_NNP profit_NN and_CC loss_NN account_NN ,_, resulting_VBG from_IN the_DT revaluation_NN of_IN this_DT US_NNP dollar-denominated_JJ facility_NN ._.
19_CD Creditors_NNS :_: amounts_NNS falling_VBG after_IN one_CD year_NN Group_NNP Company_NNP 2002 2001 2002 2001_CD 000 000 000 000_CD Obligations_NNS under_IN finance_NN leases_NNS 13,972_CD 14,299_CD -_: -_: Accruals_NNP and_CC deferred_JJ income_NN 4,925_CD 6,235_CD -_: -_: 18,897_CD 20,534_CD -_: -_: The_DT amount_NN in_IN accruals_NNS and_CC deferred_JJ income_NN relates_VBZ to_TO the_DT insurance_NN premiums_NNS ,_, payable_JJ on_IN behalf_NN of_IN the_DT CDC_NNP ,_, relating_VBG to_TO the_DT first_JJ CDC_NNP smallpox_NN vaccine_NN contract_NN ,_, the_DT equivalent_JJ figure_NN being_VBG included_VBN in_IN Debtors_NNS ,_, as_IN referred_VBN to_TO in_IN note_NN 17_CD above_IN ._.
In_IN December_NNP 2001_CD ,_, the_DT Group_NNP committed_VBD to_TO a_DT finance_NN lease_NN ,_, repayable_JJ within_IN five_CD years_NNS ,_, relating_VBG to_TO the_DT purchase_NN and_CC sale-and-leaseback_NN of_IN capital_NN assets_NNS within_IN the_DT manufacturing_NN plant_NN ._.
Further_JJ details_NNS regarding_VBG this_DT finance_NN lease_NN facility_NN are_VBP given_VBN within_IN Financial_NNP liabilities_NNS in_IN note_NN 20_CD ._.
20_CD Financial_NNP instruments_NNS 11_CD The_DT Groups_NNS financial_JJ instruments_NNS comprise_VBP primarily_RB cash_NN and_CC liquid_JJ resources_NNS ,_, a_DT long-term_JJ finance_NN lease_NN ,_, an_DT overdraft_NN facility_NN and_CC various_JJ items_NNS ,_, such_JJ as_IN trade_NN debtors_NNS and_CC trade_NN creditors_NNS ,_, that_IN arise_VB directly_RB from_IN its_PRP$ operations_NNS ._.
The_DT main_JJ purpose_NN of_IN these_DT financial_JJ instruments_NNS is_VBZ to_TO provide_VB working_JJ capital_NN for_IN the_DT Groups_NNS operations_NNS ._.
The_DT Group_NNP holds_VBZ funds_NNS in_IN both_DT US_NNP dollars_NNS and_CC sterling_NN ._.
The_DT Groups_NNS current_JJ policy_NN is_VBZ to_TO hold_VB surplus_NN funds_NNS in_IN sterling_NN over_IN the_DT long_JJ term_NN ,_, which_WDT currently_RB achieves_VBZ a_DT higher_JJR interest_NN rate_NN return_NN ,_, whilst_NN also_RB mitigating_VBG exchange_NN rate_NN exposure_NN ._.
The_DT main_JJ risks_NNS arising_VBG from_IN the_DT Groups_NNS financial_JJ instruments_NNS are_VBP interest_NN rate_NN risk_NN ,_, liquidity_NN risk_NN and_CC foreign_JJ currency_NN risk_NN ._.
The_DT Board_NNP reviews_NNS and_CC agrees_VBZ policies_NNS for_IN managing_VBG each_DT of_IN these_DT risks_NNS ._.
These_DT policies_NNS have_VBP remained_VBN unchanged_JJ since_IN the_DT beginning_NN of_IN 2000_CD ._.
All_DT of_IN the_DT Groups_NNS short-term_JJ debtors_NNS and_CC creditors_NNS are_VBP excluded_VBN from_IN these_DT disclosures_NNS ,_, other_JJ than_IN currency_NN risk_NN disclosures_NNS ._.
Interest_NN rate_NN risk_NN The_DT Group_NNP finances_VBZ its_PRP$ operations_NNS predominantly_RB through_IN cash_NN ,_, liquid_JJ resources_NNS and_CC lease_NN financing_NN ._.
It_PRP is_VBZ the_DT Groups_NNS policy_NN to_TO invest_VB surplus_NN cash_NN in_IN money_NN market_NN funds_NNS ,_, managed_VBN by_IN professional_JJ money_NN managers_NNS ._.
The_DT performance_NN of_IN the_DT funds_NNS invested_VBN is_VBZ reviewed_VBN by_IN the_DT Board_NNP on_IN a_DT regular_JJ basis_NN to_TO ensure_VB that_IN competitive_JJ rates_NNS of_IN return_NN are_VBP being_VBG achieved_VBN ._.
The_DT Board_NNP reviews_VBZ regularly_RB the_DT financing_NN facilities_NNS available_JJ to_TO the_DT Group_NNP to_TO ensure_VB competitive_JJ rates_NNS of_IN interest_NN are_VBP being_VBG obtained_VBN ._.
Liquidity_NN risk_NN The_NNP Board_NNP monitors_VBZ the_DT level_NN of_IN cash_NN and_CC liquid_JJ resources_NNS on_IN a_DT regular_JJ basis_NN ,_, and_CC management_NN on_IN a_DT daily_JJ basis_NN ,_, to_TO ensure_VB that_IN the_DT Group_NNP has_VBZ sufficient_JJ liquid_NN funds_NNS THE_DT INFORMATION_NN CONTAINED_VBD IN_IN THIS_NNP COLUMN_NNP to_TO enable_VB it_PRP to_TO continue_VB as_IN a_DT going_VBG concern_NN ._.
This_DT is_VBZ achieved_VBN through_IN the_DT production_NN and_CC review_NN of_IN cash_NN forecasts_NNS ,_, including_VBG sensitivity_NN analyses_NNS ._.
The_DT Groups_NNS liquid_JJ HAS_VBZ NOT_RB BEEN_JJ AUDITED_NN ._.
31_CD resources_NNS are_VBP managed_VBN on_IN a_DT discretionary_JJ basis_NN by_IN a_DT third_JJ party_NN within_IN strict_JJ parameters_NNS ,_, which_WDT have_VBP been_VBN set_VBN by_IN the_DT Board_NNP ._.
32_CD NOTES_NNS TO_TO GROUP_NNP FINANCIAL_NNP STATEMENTS_NNP 31_CD December_NNP 2002_CD 20_CD Financial_NNP instruments_NNS continued_VBD Foreign_JJ currency_NN risk_NN The_DT Group_NNP has_VBZ one_CD principal_NN subsidiary_NN that_WDT operates_VBZ and_CC trades_VBZ overseas_JJ Acambis_NNP Inc._NNP ._.
It_PRP operates_VBZ in_IN the_DT US_NNP and_CC its_PRP$ revenues_NNS ,_, expenses_NNS and_CC financing_NN are_VBP denominated_VBN principally_RB in_IN US_NNP dollars_NNS ._.
The_DT Group_NNP has_VBZ a_DT US_NNP dollar-denominated_JJ overdraft_NN facility_NN ,_, as_IN described_VBN in_IN note_NN 18_CD ,_, which_WDT is_VBZ held_VBN in_IN the_DT UK_NNP and_CC is_VBZ subject_JJ to_TO exchange_VB rate_NN movements_NNS ._.
These_DT are_VBP recognized_VBN as_IN incurred_VBN ._.
In_IN addition_NN ,_, the_DT Group_NNP has_VBZ other_JJ current_JJ assets_NNS and_CC liabilities_NNS denominated_VBN in_IN foreign_JJ currencies_NNS ,_, which_WDT the_DT Board_NNP does_VBZ not_RB consider_VB to_TO be_VB significant_JJ ._.
The_DT tables_NNS below_IN show_VBP the_DT extent_NN to_TO which_WDT Group_NNP companies_NNS have_VBP monetary_JJ assets_NNS and_CC liabilities_NNS in_IN currencies_NNS other_JJ than_IN their_PRP$ local_JJ currency_NN ._.
Net_JJ foreign_JJ currency_NN monetary_JJ assets_NNS liabilities_NNS 2001_CD Sterling_NNP US_NNP dollar_NN Euros_NNP Total_NNP 000 000 000 000_CD Functional_JJ currency_NN of_IN Group_NNP operation_NN :_: Sterling_NNP -28,782_SYM -_: 28,782_CD US_NNP dollars_NNS --_: -_: -_: -28,782_SYM -_: 28,782_CD 2002_CD Sterling_NNP US_NNP dollar_NN Euros_NNP Total_NNP 000 000 000 000_CD Functional_JJ currency_NN of_IN Group_NNP operation_NN :_: Sterling_NNP -27,399_CD 755_CD 28,154_CD US_NNP dollars_NNS --_: -_: -_: -27,399_CD 755_CD 28,154_CD Financial_JJ assets_NNS The_DT Group_NNP had_VBD cash_NN and_CC liquid_JJ resources_NNS of_IN 11.8_CD m_NN at_IN 31_CD December_NNP 2002_CD 2001_CD 22.2_CD m._NN The_DT majority_NN of_IN these_DT resources_NNS are_VBP invested_VBN in_IN managed_VBN funds_NNS ,_, denominated_VBN in_IN sterling_NN and_CC US_NNP dollars_NNS ,_, and_CC are_VBP available_JJ for_IN use_NN with_IN a_DT days_NNS notice_NN ._.
During_IN 2002_CD ,_, these_DT funds_NNS achieved_VBD weighted_JJ average_JJ returns_NNS of_IN 4.1_CD %_NN 2001_CD 5.4_CD %_NN for_IN funds_NNS invested_VBN in_IN UK_NNP sterling_NN ,_, and_CC 1.9_CD %_NN 2001_CD 4.7_CD %_NN for_IN funds_NNS invested_VBN in_IN US_NNP dollars_NNS ._.
The_DT Group_NNP also_RB holds_VBZ shares_NNS in_IN Medivir_NNP AB_NNP see_VBP note_NN 14_CD b._NN This_DT investment_NN does_VBZ not_RB subject_JJ the_DT Group_NNP to_TO interest_NN rate_NN risk_NN as_IN it_PRP has_VBZ no_DT maturity_NN date_NN ._.
Financial_NNP liabilities_NNS The_DT Groups_NNS overdraft_NN facility_NN ,_, which_WDT is_VBZ denominated_VBN in_IN US_NNP dollars_NNS and_CC is_VBZ underwritten_VBN by_IN PowderJect_NNP ,_, is_VBZ explained_VBN in_IN note_NN 18_CD ._.
At_IN 31_CD December_NNP 2002_CD ,_, the_DT Group_NNP had_VBD fully_RB utilised_VBN the_DT overdraft_NN facility_NN 2001_CD fully_RB utilised_VBN ._.
Interest_NN on_IN the_DT facility_NN is_VBZ charged_VBN at_IN 0.35_CD %_NN per_IN annum_NN above_IN the_DT bank-lending_JJ rate_NN for_IN US_NNP dollars_NNS ._.
During_IN 2002_CD ,_, the_DT weighted_JJ average_JJ interest_NN payable_JJ on_IN the_DT facility_NN was_VBD 2.0_CD %_NN 2001_CD 4.5_CD %_NN ._.
The_DT only_JJ other_JJ financial_JJ liability_NN of_IN the_DT Group_NNP at_IN 31_CD December_NNP 2002_CD was_VBD a_DT long-term_JJ lease-finance_NN facility_NN ,_, which_WDT matures_VBZ within_IN four_CD years_NNS ._.
This_DT $_$ 40m_CD c._NN 25m_JJ leasefinance_NN facility_NN ,_, arranged_VBN through_IN Baxter_NNP International_NNP ,_, Inc._NNP ._.
Baxter_NNP ,_, was_VBD approved_VBN by_IN shareholders_NNS in_IN December_NNP 2001_CD ._.
The_DT Group_NNP secured_VBN financing_NN of_IN $_$ 10m_CD c._NN 6.8_CD m_NN for_IN the_DT sale-and-leaseback_NN of_IN the_DT land_NN and_CC shell_NN of_IN the_DT manufacturing_NN plant_NN ,_, and_CC up_RB to_TO $_$ 25m_CD c._NN 17m_CD to_TO lease-finance_VB the_DT capital_NN expenditure_NN items_NNS purchased_VBD to_TO reactivate_VB the_DT manufacturing_NN plant_NN ._.
In_IN December_NNP 2001_CD ,_, the_DT Group_NNP received_VBD $_$ 18.6_CD m_NN c._NN 12.8_CD m_NN ,_, which_WDT represented_VBD $_$ 8.6_CD m_NN c._NN 6.0_CD m_NN in_IN respect_NN of_IN capital_NN expenditure_NN already_RB incurred_VBN throughout_IN 2001_CD ,_, plus_CC $_$ 10m_CD c._NN 6.8_CD m_NN representing_VBG the_DT net_JJ proceeds_NNS from_IN sale-and-leaseback_NN of_IN the_DT land_NN and_CC shell_NN of_IN the_DT building_NN ._.
To_TO facilitate_VB this_DT transaction_NN ,_, the_DT land_NN and_CC shell_NN were_VBD purchased_VBN for_IN $_$ 2.3_CD m_NN c._NN 1.5_CD m._FW This_DT amount_NN is_VBZ included_VBN in_IN the_DT outstanding_JJ facility_NN ._.
During_IN 2002_CD ,_, no_DT further_JJ draw_NN downs_NNS were_VBD made_VBN from_IN the_DT facility_NN ,_, although_IN interest_NN of_IN $_$ 1.7_CD m_NN 1.1_CD m_NN accrued_VBN during_IN the_DT year_NN and_CC has_VBZ converted_VBN into_IN the_DT capital_NN balance_NN owing_NN on_IN the_DT facility_NN ._.
The_DT financing_NN has_VBZ been_VBN reflected_VBN in_IN the_DT financial_JJ statements_NNS as_IN a_DT long-term_JJ creditor_NN ._.
During_IN 2002_CD ,_, interest_NN was_VBD charged_VBN to_TO the_DT facility_NN at_IN 3_CD %_NN above_IN the_DT prime_JJ rate_NN of_IN Banc_NNP One_CD Corporation_NNP ,_, a_DT USbased_JJ bank_NN ,_, resulting_VBG in_IN an_DT interest_NN charge_NN of_IN 1.1_CD m_NN 2001_CD 0.03_CD m_NN being_VBG added_VBN to_TO the_DT facility_NN ._.
From_IN January_NNP 2003_CD ,_, the_DT interest_NN percentage_NN payable_JJ in_IN respect_NN of_IN the_DT facility_NN has_VBZ been_VBN fixed_VBN at_IN 6.25_CD %_NN until_IN the_DT end_NN of_IN the_DT life_NN of_IN the_DT lease_NN ._.
The_DT repayment_NN schedule_NN for_IN the_DT lease_NN financing_NN requires_VBZ that_IN no_DT interest_NN or_CC capital_NN were_VBD repayable_JJ during_IN 2002_CD ,_, interest_NN only_RB need_MD be_VB repaid_VBN in_IN 2003_CD and_CC capital_NN and_CC interest_NN are_VBP repayable_JJ over_IN 2004_CD to_TO 2006_CD ._.
The_DT Group_NNP has_VBZ an_DT option_NN to_TO repurchase_VB all_DT of_IN the_DT facilitys_NNS assets_NNS from_IN the_DT end_NN of_IN 2003_CD ,_, and_CC on_IN each_DT anniversary_NN thereafter_RB ,_, for_IN the_DT capital_NN balance_NN outstanding_JJ at_IN that_DT time_NN ,_, plus_CC any_DT accrued_VBN but_CC unpaid_JJ interest_NN due_JJ at_IN the_DT time_NN ,_, plus_CC a_DT make-whole_JJ payment_NN discounted_VBN to_TO present_JJ value_NN equal_JJ to_TO the_DT projected_VBN future_JJ interest_NN stream_NN payable_JJ to_TO the_DT end_NN of_IN the_DT lease_NN term_NN ._.
At_IN 31_CD December_NNP 2002_CD ,_, the_DT balance_NN on_IN this_DT facility_NN was_VBD $_$ 22.5_CD m_NN 14.0_CD m_NN ,_, resulting_VBG in_IN $_$ 17.5_CD m_NN c._NN 10.9_CD m_NN not_RB being_VBG used_VBN at_IN that_DT time_NN 2001_CD $_$ 19.2_CD m._FW The_DT facility_NN is_VBZ Profile_NNP of_IN Groups_NNS financial_JJ denominated_VBN in_IN US_NNP dollars_NNS ._.
liabilities_NNS -_: finance_NN lease_NN This_DT relates_VBZ to_TO the_DT financing_NN put_VBN in_IN Profile_NNP of_IN the_DT Groups_NNS financial_JJ liabilities_NNS place_VBP for_IN our_PRP$ manufacturing_NN plant_NN The_DT maturity_NN profile_NN of_IN the_DT overdraft_NN facility_NN ,_, together_RB with_IN the_DT future_JJ minimum_NN finance_NN lease_NN obligations_NNS net_NN of_IN finance_NN charges_NNS to_TO which_WDT the_DT Group_NNP is_VBZ committed_VBN are_VBP in_IN 2001_CD ._.
We_PRP have_VBP an_DT option_NN to_TO as_IN follows_VBZ :_: repurchase_VBD the_DT plant_NN and_CC all_DT of_IN its_PRP$ assets_NNS in_IN December_NNP 2003_CD on_IN Overdraft_NN faciity_NN Finance_NNP lease_NN 2002_CD Overdraft_NN faciity_NN Finance_NNP lease_NN 2001_CD the_DT second_JJ anniversary_NN of_IN the_DT 000 000 000 000_CD 000_CD 000_CD establishment_NN of_IN the_DT agreement_NN ,_, Within_IN one_CD and_CC two_CD years_NNS 4,349_CD 4,428_CD 8,777_CD 4,809_CD -_: 4,809_CD and_CC on_IN each_DT anniversary_NN thereafter_RB ,_, Between_IN two_CD and_CC five_CD years_NNS -9,544_CD 9,544_CD -14,299_CD 14,299_CD for_IN the_DT outstanding_JJ capital_NN balance_NN ._.
4,349_CD 13,972_CD 18,321_CD 4,809_CD 14,299_CD 19,108_CD Share_NN option_NN schemes_NNS Fair_NNP values_NNS of_IN financial_JJ assets_NNS and_CC financial_JJ liabilities_NNS We_PRP recognize_VBP that_IN our_PRP$ people_NNS are_VBP In_IN the_DT opinion_NN of_IN the_DT Directors_NNS ,_, there_EX is_VBZ no_DT material_NN difference_NN between_IN the_DT book_NN values_NNS and_CC fair_JJ values_NNS of_IN the_DT Groups_NNS financial_JJ assets_NNS and_CC liabilities_NNS as_IN at_IN 31_CD December_NNP one_CD of_IN our_PRP$ most_RBS important_JJ assets_NNS 2002_CD ._.
Fair_NNP values_NNS have_VBP been_VBN calculated_VBN by_IN discounting_VBG cash_NN flows_NNS at_IN prevailing_VBG interest_NN rates_NNS ._.
and_CC encourage_VB all_DT employees_NNS to_TO share_VB in_IN the_DT growth_NN of_IN the_DT Group_NNP by_IN 21_CD Called-up_JJ share_NN capital_NN Year_NN ending_VBG 31_CD December_NNP 2002_CD Year_NN ending_VBG 31_CD December_NNP 2001_CD offering_NN share_NN options_NNS to_TO every_DT Number_NN 000_CD Number_NNP 000_CD employee_NN ._.
The_DT subscription_NN is_VBZ payable_JJ in_IN instalments_NNS between_IN December_NNP 2000_CD and_CC ,_, at_IN the_DT latest_JJS ,_, June_NNP 2003_CD ._.
The_DT subscription_NN price_NN in_IN 2002_CD was_VBD 1.40_CD 2001_CD 1.30_CD per_IN ordinary_JJ share_NN ._.
As_IN described_VBN within_IN Post_NNP balance_NN sheet_NN events_NNS on_IN page_NN 37_CD ,_, on_IN 27_CD March_NNP 2003_CD ,_, Baxter_NNP accelerated_VBD its_PRP$ fourth_JJ and_CC final_JJ subscription_NN ,_, taking_VBG its_PRP$ shareholding_NN to_TO 20.6_CD %_NN ._.
Share_NN option_NN schemes_NNS The_DT Group_NNP operates_VBZ several_JJ share_NN option_NN schemes_NNS ._.
Notes_NNP 1_CD The_DT Peptide_NNP Therapeutics_NNP Group_NNP plc_NN 1994_CD Unapproved_NNP Share_NNP Option_NN Scheme_NN ._.
2_CD Parallel_JJ options_NNS under_IN the_DT 1995_CD Scheme_NN existed_VBD over_IN 14,015_CD of_IN the_DT options_NNS outstanding_JJ at_IN 31_CD December_NNP 2002_CD ._.
Option_NN holders_NNS may_MD elect_VB to_TO exercise_VB either_DT option_NN ,_, at_IN which_WDT time_NN the_DT alternative_NN option_NN lapses_NNS ._.
The_DT Group_NNP operates_VBZ an_DT Inland_NNP Revenue-approved_JJ Save-As-You-Earn_NNP SAYE_NNP scheme_NN in_IN the_DT UK_NNP and_CC has_VBZ taken_VBN advantage_NN of_IN the_DT exemption_NN given_VBN in_IN UITF_NNP 17_CD from_IN recognizing_VBG a_DT charge_NN in_IN the_DT profit_NN and_CC loss_NN account_NN for_IN the_DT discount_NN on_IN those_DT options_NNS ._.
At_IN the_DT Annual_JJ General_NNP Meeting_VBG to_TO be_VB held_VBN on_IN 13_CD May_NNP 2003_CD ,_, the_DT Directors_NNS will_MD seek_VB the_DT authority_NN of_IN shareholders_NNS to_TO introduce_VB a_DT new_JJ all-employee_JJ share_NN plan_NN for_IN US-based_JJ employees_NNS ,_, which_WDT is_VBZ similar_JJ to_TO the_DT SAYE_NNP scheme_NN in_IN the_DT UK_NNP ._.
22_CD Reserves_NNS 2002 2001 2000_CD Share_NN premium_NN account_NN Share_NN premium_NN Profit_NN and_CC loss_NN Share_NN premium_NN Profit_NN and_CC loss_NN Share_NN premium_NN Profit_NN and_CC loss_NN account_NN account_NN account_NN account_NN account_NN account_NN Acambis_NNP ordinary_JJ shares_NNS have_VBP a_DT Group_NNP reserves_NNS 000 000 000 000_CD 000_CD 000_CD nominal_JJ value_NN of_IN 10p_CD ._.
When_WRB new_JJ At_IN 1_CD January_NNP 80,598_CD 62,246_CD 76,776_CD 49,505_CD 67,456_CD 37,614_CD shares_NNS are_VBP issued_VBN ,_, either_CC through_IN Issue_NN of_IN new_JJ shares_NNS 7,147_CD -_: 3,822_SYM -_: 9,320_CD -_: fundraisings_NNS ,_, share_NN option_NN exercises_VBZ Exchange_NNP adjustments_NNS -_: 1,276_SYM -_: 314_CD -_: 817_CD or_CC corporate_JJ transactions_NNS such_JJ as_IN Retained_JJ profit_NN loss_NN for_IN the_DT year_NN -9,575_CD -_: 12,427_SYM -_: 11,074_CD the_DT subscription_NN agreement_NN with_IN At_IN 31_CD December_NNP 87,745_CD 51,395_CD 80,598_CD 62,246_CD 76,776_CD 49,505_CD Baxter_NNP ,_, the_DT price_NN paid_VBN for_IN the_DT shares_NNS 2002 2001 2000_CD in_IN excess_NN of_IN the_DT 10p_JJ nominal_JJ value_NN is_VBZ Share_NN premium_NN Profit_NN and_CC loss_NN Share_NN premium_NN Profit_NN and_CC loss_NN Share_NN premium_NN Profit_NN and_CC loss_NN recognized_VBN as_IN share_NN premium_NN ._.
account_NN account_NN account_NN account_NN account_NN account_NN Company_NN reserves_NNS 000 000 000 000_CD 000_CD 000_CD At_IN 1_CD January_NNP 80,464_CD 4,719_CD 76,642_CD 99_CD 67,322_CD 132_CD Issue_NN of_IN new_JJ shares_NNS 7,147_CD -_: 3,822_SYM -_: 9,320_CD -_: Exchange_NNP adjustments_NNS -_: 1,459_SYM -_: -_: -_: -_: Retained_VBN loss_NN profit_NN for_IN the_DT year_NN -_: 1,621_CD -_: 4,620_SYM -_: 33_CD At_IN 31_CD December_NNP 87,611_CD 1,639_CD 80,464_CD 4,719_CD 76,642_CD 99_CD 23_CD Reconciliation_NNP of_IN movements_NNS in_IN Group_NNP shareholders_NNS funds_NNS 2002 2001 000 000_CD Retained_VBN profit_NN loss_NN for_IN the_DT period_NN 9,575_CD 12,427_CD Gain_NNP loss_NN on_IN foreign_JJ currency_NN exchange_NN 1,276_CD 314_CD New_NNP share_NN capital_NN subscribed_VBN 7,740_CD 4,262_CD Net_JJ increase_NN decrease_NN in_IN shareholders_NNS funds_NNS 18,591_CD 8,479_CD Opening_NN shareholders_NNS funds_NNS 27,660_CD 36,139_CD Closing_NN shareholders_NNS funds_NNS 46,251_CD 27,660_CD 24_CD Reconciliation_NNP of_IN the_DT operating_NN profit_NN loss_NN to_TO net_JJ cash_NN outflow_NN from_IN operating_VBG activities_NNS 2002 2001 2000 000_CD 000_CD 000_CD Operating_NN profit_NN loss_NN 9,911_CD 12,242_CD 9,397_CD Depreciation_NN and_CC amortisation_NN 2,614_CD 1,942_CD 2,132_CD Increase_VBP in_IN stock_NN 52,631_CD --_: Increase_VB in_IN debtors_NNS 50,602_CD 3,685_CD 8,558_CD Increase_VBP in_IN creditors_NNS 81,798_CD 5,685_CD 6,607_CD Loss_NN on_IN sale_NN of_IN tangible_JJ fixed_JJ assets_NNS 9_CD -_: 6_CD Exchange_NNP differences_NNS arising_VBG on_IN inter-company_JJ balances_NNS 1,274_CD 499_CD 691_CD Other_JJ 1,445_CD 840_CD 694_CD Net_JJ cash_NN outflow_NN from_IN operating_VBG activities_NNS 6,182_CD 7,959_CD 9,207_CD In_IN 2001_CD and_CC 2002_CD ,_, all_DT cash_NN flows_VBZ arose_VBD from_IN continuing_VBG operating_NN activities_NNS ._.
35_CD 36_CD NOTES_NNS TO_TO GROUP_NNP FINANCIAL_NNP STATEMENTS_NNP 31_CD December_NNP 2002_CD 25_CD Analysis_NN and_CC reconciliation_NN of_IN net_JJ funds_NNS debt_NN Net_JJ debt_NN 1_CD January_NNP 2001_CD Cash_NN flow_NN Non-cash_JJ movements_NNS Exchange_NNP movement_NN 31_CD December_NNP 2001 000 000 000_CD 000_CD 000_CD As_IN a_DT result_NN of_IN the_DT major_JJ working_JJ capital_NN requirements_NNS for_IN the_DT second_JJ Cash_NN 1,179_CD 20,910_CD -_: 4_CD 22,093_CD CDC_NNP smallpox_NN vaccine_NN contract_NN ,_, cash_NN Liquid_NN resources_NNS 19,938_CD 19,834_CD -_: 16_CD 120_CD Overdraft_NN facility_NN 4,686_CD -_: -_: 124_CD 4,810_CD and_CC liquid_JJ resources_NNS at_IN the_DT year-end_JJ 1,076_CD of_IN 11.8_CD million_CD was_VBD less_JJR than_IN our_PRP$ Finance_NNP lease_NN 13_CD 12,725_CD 1,546_CD 15_CD 14,299_CD obligations_NNS under_IN the_DT finance_NN lease_NN Net_JJ funds_NNS 16,418_CD 11,649_CD 1,546_CD 119_CD 3,104_CD and_CC overdraft_NN facilities_NNS ._.
However_RB ,_, this_DT was_VBD simply_RB the_DT result_NN of_IN timing_VBG 1_CD January_NNP 2002_CD Cash_NN flow_NN Non-cash_JJ movements_NNS Exchange_NNP movement_NN 31_CD December_NNP 2002_CD differences_NNS in_IN payments_NNS ._.
Two_CD days_NNS 000 000 000 000_CD 000_CD following_VBG the_DT 2002_CD year-end_NN our_PRP$ Cash_NN 22,093_CD 9,179_CD -_: 1,242_CD 11,672_CD cash_NN was_VBD such_JJ that_IN net_JJ funds_NNS of_IN the_DT Liquid_NN resources_NNS 120_CD 5_LS -_: 10_CD 105_CD Group_NNP were_VBD once_RB again_RB positive_JJ ._.
Overdraft_NN facility_NN 4,810_CD -_: -_: 461_CD 4,349_CD 9,184_CD Finance_NNP lease_NN 14,299_CD -_: 1,118_CD 1,445_CD 13,972_CD Net_JJ debt_NN 3,104_CD 9,184_CD 1,118_CD 654_CD 6,544_CD Liquid_NN resources_NNS at_IN 31_CD December_NNP 2002_CD of_IN 0.1_CD m_NN represents_VBZ amounts_NNS held_VBN by_IN Acambis_NNP Inc._NNP as_IN a_DT deposit_NN against_IN property_NN rentals_NNS ._.
2002 2001 2000 000_CD 000_CD 000_CD Decrease_NN increase_NN in_IN cash_NN 9,179_CD 20,910_CD 351_CD Decrease_NN increase_NN in_IN liquid_JJ resources_NNS 5_CD 19,834_CD 1,894_CD Decrease_NN increase_NN in_IN cash_NN and_CC liquid_JJ resources_NNS 9,184_CD 1,076_CD 1,543_CD Net_JJ cash_NN outflow_NN from_IN lease_NN financing_NN -_: 13_CD 29_CD Proceeds_NNS from_IN new_JJ finance_NN lease_NN -_: 12,738_CD -_: Net_JJ increase_NN in_IN overdraft_NN facility_NN -_: -_: 2,502_CD Change_NNP in_IN net_JJ debt_NN funds_NNS arising_VBG from_IN cash_NN flows_NNS 9,184_CD 11,649_CD 930_CD Non-cash_JJ element_NN of_IN finance_NN lease_NN 1,118_CD 1,546_CD -_: Exchange_NNP adjustments_NNS 654_CD 119_CD 59_CD Movement_NNP in_IN net_JJ debt_NN funds_NNS 9,648_CD 13,314_CD 989_CD Net_JJ funds_NNS at_IN 1_CD January_NNP 3,104_CD 16,418_CD 17,407_CD Net_JJ debt_NN funds_NNS at_IN 31_CD December_NNP 6,544_CD 3,104_CD 16,418_CD 26_CD Financial_NNP commitments_NNS a_DT Lease_NNP commitments_NNS The_DT minimum_JJ annual_JJ rentals_NNS payable_JJ by_IN the_DT Group_NNP under_IN non-cancellable_JJ operating_NN leases_NNS are_VBP as_IN follows_VBZ :_: Land_NNP and_CC buildings_NNS Equipment_NNP 2002 2001 2002 2001_CD 000 000 000 000_CD Operating_NN leases_NNS which_WDT expire_VBP :_: Within_IN one_CD year_NN 31_CD -_: 13_CD -_: Within_IN two_CD to_TO five_CD years_NNS 1,640_CD 962_CD -_: 6_CD After_IN more_JJR than_IN five_CD years_NNS -_: 520_CD -_: -_: 1,671_CD 1,482_CD 13_CD 6_CD At_IN 31_CD December_NNP 2002_CD ,_, the_DT Company_NN had_VBD no_DT operating_NN leases_VBZ 2001_CD nil_NN ._.
In_IN March_NNP 2000_CD ,_, the_DT Group_NNP entered_VBD into_IN a_DT sub-lease_NN with_IN Medivir_NNP UK_NNP Limited_NNP in_IN respect_NN of_IN 50_CD %_NN of_IN the_DT facility_NN at_IN Peterhouse_NNP Technology_NNP Park_NNP in_IN the_DT UK_NNP ._.
The_DT sub-lease_NN expires_VBZ in_IN September_NNP 2003_CD ,_, and_CC provides_VBZ that_IN Medivir_NNP UK_NNP Limited_NNP will_MD pay_VB Acambis_NNP 0.3_CD m_FW per_FW annum_NN in_IN operating_VBG lease_NN rentals_NNS relating_VBG to_TO land_NN and_CC buildings_NNS ._.
In_IN September_NNP 1999_CD ,_, the_DT Group_NNP entered_VBD a_DT further_JJ sub-lease_NN with_IN Millennium_NNP Pharmaceuticals_NNP ,_, Inc._NNP in_IN respect_NN of_IN 25_CD %_NN of_IN the_DT facility_NN at_IN 38_CD Sidney_NNP Street_NNP in_IN Cambridge_NNP ,_, Massachusetts_NNP ,_, USA_NNP ._.
This_DT sub-lease_NN expired_VBD in_IN December_NNP 2002_CD at_IN which_WDT point_NN Acambis_NNP re-occupied_VBD all_DT of_IN this_DT space_NN ._.
b_NN Capital_NN commitments_NNS At_IN the_DT end_NN of_IN the_DT year_NN ,_, capital_NN commitments_NNS contracted_VBD but_CC not_RB provided_VBN for_IN were_VBD 0.1_CD m_NN 2001_CD 6.4_CD m._NN c_NN Pension_NN arrangements_NNS The_DT Group_NNP provides_VBZ pension_NN benefits_NNS to_TO all_DT full-time_JJ employees_NNS on_IN a_DT defined_VBN contribution_NN basis_NN ._.
The_DT Company_NN operates_VBZ a_DT self-administered_JJ ,_, Inland_NNP Revenue-approved_JJ pension_NN scheme_NN for_IN UK_NNP Executive_NNP Directors_NNS ._.
Other_JJ employees_NNS may_MD operate_VB private_JJ personal_JJ pension_NN schemes_NNS ._.
In_IN the_DT US_NNP the_DT Group_NNP offers_VBZ a_DT 401k_JJ Savings_NNS and_CC Retirement_NNP Plan_NNP for_IN all_DT employees_NNS ,_, including_VBG Executive_NNP Directors_NNS ._.
The_DT Group_NNP pension_NN cost_NN including_VBG 401k_JJ costs_NNS for_IN the_DT year_NN was_VBD 0.5_CD m_NN 2001_CD 0.2_CD m._NN At_IN the_DT year-end_NN ,_, the_DT Group_NNP owed_VBD 0.2_CD m_NN 2001_CD 0.01_CD m_NN to_TO the_DT pension_NN schemes_NNS ._.
This_DT amount_NN is_VBZ shown_VBN in_IN the_DT balance_NN sheet_NN under_IN Creditors_NNPS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN ._.
27_CD Related_VBN party_NN transactions_NNS 7b_VBP Under_IN the_DT provisions_NNS of_IN FRS_NNP 8_CD ,_, Related_NNP Party_NNP Disclosures_NNS ,_, it_PRP is_VBZ not_RB necessary_JJ to_TO disclose_VB related_JJ party_NN transactions_NNS between_IN the_DT Company_NN ,_, Acambis_NNP Research_NNP Limited_NNP and_CC Acambis_NNP Inc._NNP because_IN they_PRP are_VBP eliminated_VBN on_IN preparation_NN of_IN the_DT Groups_NNS financial_JJ statements_NNS ._.
As_IN described_VBN in_IN note_NN 14_CD d_LS ,_, the_DT Group_NNP has_VBZ an_DT interest_NN in_IN the_DT Joint_NNP Venture_NNP ._.
Since_IN May_NNP 1999_CD ,_, Acambis_NNP has_VBZ performed_VBN a_DT pre-agreed_JJ work_NN program_NN on_IN behalf_NN of_IN the_DT Joint_NNP Venture_NNP ._.
Costs_NNS incurred_VBN by_IN the_DT Group_NNP on_IN behalf_NN of_IN the_DT Joint_NNP Venture_NNP and_CC corresponding_JJ turnover_NN received_VBN from_IN the_DT Joint_NNP Venture_NNP have_VBP been_VBN included_VBN in_IN the_DT Groups_NNS financial_JJ statements_NNS ._.
For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ,_, the_DT Group_NNP has_VBZ included_VBN turnover_NN of_IN 0.3_CD m_NN 2001_CD 0.5_CD m_NN in_IN respect_NN of_IN costs_NNS incurred_VBN in_IN performing_VBG services_NNS for_IN the_DT Joint_NNP Venture_NNP within_IN its_PRP$ Group_NNP financial_JJ statements_NNS ._.
50_CD %_NN of_IN the_DT loss_NN incurred_VBN by_IN Pasteur_NNP Mrieux-OraVax_NNP in_IN 2002_CD ,_, amounting_VBG to_TO 0.2_CD m_NN 2001_CD 0.4_CD m_NN ,_, is_VBZ shown_VBN on_IN the_DT face_NN of_IN the_DT Group_NNP profit_NN and_CC loss_NN account_NN on_IN page_NN 18_CD ._.
At_IN 31_CD December_NNP 2002_CD ,_, the_DT amounts_NNS the_DT Group_NNP owed_VBD to_TO the_DT Joint_NNP Venture_NNP amounted_VBD to_TO nil_VB 2001_CD 0.5_CD m._NN Amounts_NNS owed_VBN by_IN the_DT Joint_NNP Venture_NNP to_TO the_DT Group_NNP at_IN 31_CD December_NNP 2002_CD were_VBD nil_JJ 2001_CD nil_NN ._.
In_IN 2002_CD ,_, the_DT Group_NNP took_VBD the_DT view_NN that_IN ,_, taking_VBG into_IN account_NN the_DT increase_NN in_IN its_PRP$ shareholding_NN in_IN Acambis_NNP and_CC the_DT presence_NN of_IN a_DT representative_NN from_IN Baxter_NNP on_IN the_DT Board_NNP ,_, Baxters_NNP influence_NN on_IN Acambis_NNP became_VBD significant_JJ ,_, and_CC therefore_RB Baxter_NNP is_VBZ a_DT related_JJ party_NN ._.
Baxters_NNS subscriptions_NNS in_IN the_DT shares_NNS of_IN the_DT Company_NN are_VBP set_VBN out_RP in_IN note_NN C_NNP on_IN page_NN 21_CD ,_, and_CC the_DT Groups_NNS long-term_JJ lease-finance_NN facility_NN with_IN Baxter_NNP is_VBZ described_VBN within_IN Financial_NNP liabilities_NNS in_IN note_NN 20_CD ._.
The_DT Group_NNP made_VBD sales_NNS to_TO Baxter_NNP of_IN 0.7_CD m_NN in_IN 2002_CD 2001_CD nil_NN ,_, of_IN which_WDT 0.7_CD m_NN 2001_CD nil_NN was_VBD unpaid_JJ at_IN the_DT year-end_NN ,_, and_CC made_VBD purchases_NNS of_IN goods_NNS and_CC services_NNS from_IN Baxter_NNP of_IN 45.7_CD m_NN 2001_CD nil_NN ,_, of_IN which_WDT 42.7_CD m_NN 2001_CD nil_NN was_VBD unpaid_JJ at_IN the_DT year-end_NN ._.
28_CD Post_NNP balance_NN sheet_NN events_NNS Under_IN a_DT prior_JJ agreement_NN with_IN BTG_NNP International_NNP Limited_NNP BTG_NNP ,_, Acambis_NNP was_VBD required_VBN to_TO pay_VB to_TO BTG_NNP an_DT annual_JJ turnover_NN tax_NN of_IN 2_CD %_NN of_IN the_DT Groups_NNS gross_JJ turnover_NN on_IN an_DT ongoing_JJ basis_NN ._.
Following_VBG a_DT decision_NN by_IN the_DT High_NNP Court_NNP of_IN Justice_NNP Queens_NNP Bench_NNP Division_NNP in_IN the_DT UK_NNP in_IN February_NNP 2003_CD ,_, it_PRP was_VBD confirmed_VBN that_IN this_DT turnover_NN tax_NN covers_VBZ all_DT subsidiaries_NNS of_IN the_DT Company_NN ._.
This_DT decision_NN has_VBZ no_DT effect_NN on_IN the_DT financial_JJ statements_NNS of_IN the_DT Group_NNP ._.
On_IN 27_CD March_NNP 2003_CD ,_, Baxter_NNP International_NNP ,_, Inc._NNP accelerated_VBD its_PRP$ fourth_JJ and_CC final_JJ subscription_NN of_IN equity_NN shares_NNS from_IN the_DT original_JJ subscription_NN date_NN of_IN no_DT later_RB than_IN 1_CD June_NNP 2003_CD ._.
These_DT shares_NNS were_VBD traded_VBN from_IN 27_CD March_NNP 2003_CD ._.
This_DT subscription_NN of_IN 4.6_CD million_CD shares_NNS at_IN a_DT subscription_NN amount_NN of_IN 7.0_CD m_NN increased_VBD Baxters_NNP shareholding_NN in_IN the_DT Company_NN to_TO 20.6_CD %_NN ._.
37_CD 38_CD NOTES_NNS TO_TO GROUP_NNP FINANCIAL_NNP STATEMENTS_NNP 31_CD December_NNP 2002_CD 29_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS Summary_NNP of_IN significant_JJ differences_NNS between_IN UK_NNP GAAP_NNP followed_VBD by_IN the_DT Group_NNP and_CC US_NNP GAAP_NNP Compensation_NNP costs_VBZ under_IN variable_JJ The_DT Groups_NNS financial_JJ statements_NNS have_VBP been_VBN prepared_VBN under_IN UK_NNP GAAP_NNP ,_, which_WDT differs_VBZ in_IN certain_JJ respects_NNS from_IN US_NNP GAAP_NNP ._.
The_DT principal_JJ differences_NNS between_IN the_DT Groups_NNS plan_VBP accounting_VBG for_IN stock_NN options_NNS accounting_NN policies_NNS under_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP are_VBP set_VBN out_RP below_IN ._.
and_CC SAYE_NNP plan_NN discount_NN Under_IN US_NNP GAAP_NNP ,_, a_DT company_NN is_VBZ Revenue_NN recognition_NN required_VBN to_TO put_VB a_DT charge_NN through_IN its_PRP$ Revenues_NNS represent_VBP sales_NNS and_CC income_NN derived_VBN from_IN product_NN sales_NNS ,_, licence_NN fees_NNS ,_, contract_NN research_NN fees_NNS and_CC development_NN milestone_NN payments_NNS ._.
Under_IN UK_NNP GAAP_NNP ,_, these_DT profit_NN and_CC loss_NN account_NN for_IN share_NN revenues_NNS are_VBP recognized_VBN using_VBG the_DT accounting_NN policies_NNS as_IN set_VBN out_RP in_IN note_NN 1_CD ._.
The_DT Directors_NNS have_VBP selected_VBN the_DT accounting_NN policies_NNS they_PRP believe_VBP to_TO be_VB the_DT most_RBS appropriate_JJ options_NNS not_RB yet_RB exercised_VBN but_CC that_IN in_IN the_DT circumstances_NNS ,_, as_IN required_VBN by_IN FRS_NNP 18_CD Accounting_NNP Policies_NNS ._.
In_IN making_VBG this_DT judgment_NN ,_, they_PRP have_VBP taken_VBN into_IN account_NN recent_JJ publications_NNS by_IN the_DT Accounting_NN are_VBP likely_JJ to_TO be_VB exercised_VBN ._.
The_DT Standards_NNP Board_NNP ASB_NNP ,_, specifically_RB the_DT discussion_NN paper_NN entitled_VBN Revenue_NN Recognition_NN and_CC the_DT proposed_VBN additional_JJ application_NN note_NN to_TO FRS_NNP 5_CD ,_, Substance_NNP of_IN charge_NN is_VBZ calculated_VBN as_IN the_DT Transactions_NNS ._.
difference_NN between_IN the_DT market_NN value_NN of_IN the_DT shares_NNS at_IN the_DT year-end_NN For_IN US_NNP purposes_NNS ,_, the_DT Group_NNP adopted_VBD Staff_NNP Accounting_NNP Bulletin_NNP SAB_NNP 101_CD with_IN effect_NN from_IN 1_CD January_NNP 2000_CD ._.
and_CC the_DT exercise_NN price_NN ._.
Licence_NN fees_NNS Prior_RB to_TO 2001_CD ,_, under_IN UK_NNP GAAP_NNP ,_, certain_JJ licence_NN fees_NNS were_VBD recognized_VBN when_WRB paid_VBN ,_, where_WRB such_JJ payments_NNS were_VBD not_RB refundable_JJ ._.
Following_VBG the_DT Groups_NNS adoption_NN of_IN SAB101_CD under_IN US_NNP GAAP_NNP ,_, where_WRB licence_NN fees_NNS are_VBP not_RB refundable_JJ and_CC are_VBP not_RB creditable_JJ against_IN associated_VBN R&D_NNP activities_NNS ,_, these_DT fees_NNS are_VBP considered_VBN inseparable_JJ from_IN the_DT associated_VBN R&D_NNP effort_NN ._.
As_IN such_JJ ,_, those_DT licence_NN fees_NNS are_VBP deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN of_IN the_DT licence_NN term_NN or_CC over_IN the_DT period_NN of_IN the_DT R&D_NNP agreement_NN ._.
Multiple_JJ element_NN arrangements_NNS In_IN November_NNP 2001_CD ,_, Acambis_NNP was_VBD awarded_VBN a_DT second_JJ contract_NN by_IN the_DT CDC_NNP ._.
This_DT contract_NN is_VBZ divided_VBN into_IN two_CD principal_JJ components_NNS :_: to_TO manufacture_VB 155_CD million_CD doses_NNS of_IN smallpox_NN vaccine_NN :_: and_CC to_TO take_VB the_DT vaccine_NN through_IN clinical_JJ trials_NNS to_TO US_NNP Food_NNP and_CC Drug_NNP Administration_NNP FDA_NNP licensure_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, this_DT contract_NN has_VBZ been_VBN accounted_VBN for_IN as_IN a_DT single-element_JJ arrangement_NN ._.
Under_IN US_NNP GAAP_NNP ,_, the_DT Group_NNP treats_VBZ this_DT contract_NN as_IN a_DT multiple_JJ element_NN arrangement_NN resulting_VBG in_IN a_DT different_JJ allocation_NN of_IN revenue_NN compared_VBN to_TO the_DT UK_NNP GAAP_NNP treatment_NN ._.
The_DT Group_NNP has_VBZ determined_VBN the_DT fair_JJ value_NN of_IN the_DT development_NN and_CC manufacturing_NN portions_NNS of_IN the_DT contract_NN and_CC has_VBZ allocated_VBN the_DT total_JJ contract_NN value_NN to_TO the_DT development_NN and_CC manufacturing_NN using_VBG the_DT relative_JJ fair_JJ value_NN method_NN as_IN prescribed_VBN by_IN Emerging_VBG Issues_NNS Task_NNP Force_NNP EITF_NNP Issue_NNP No._NN ._.
00-21_CD ,_, Accounting_NN for_IN Revenue_NN Arrangements_NNS with_IN Multiple_NNP Deliverables_NNP ._.
The_DT development_NN portion_NN of_IN the_DT contract_NN consists_VBZ of_IN the_DT completion_NN of_IN Phase_NN I_PRP II_NNP clinical_JJ trials_NNS ,_, completion_NN of_IN Phase_NN III_NNP clinical_JJ trials_NNS including_VBG completion_NN and_CC submission_NN of_IN a_DT Biologics_NNP Licenses_NNP Application_NNP with_IN the_DT FDA_NNP and_CC post_NN FDA_NNP approval_NN activities_NNS ._.
The_DT manufacturing_NN portion_NN consists_VBZ of_IN the_DT manufacture_NN and_CC delivery_NN of_IN smallpox_NN vaccine_NN to_TO the_DT CDC_NNP ._.
The_DT Group_NNP recognizes_VBZ revenue_NN for_IN each_DT significant_JJ development_NN activity_NN on_IN a_DT straight-line_JJ basis_NN over_IN the_DT expected_VBN duration_NN of_IN each_DT respective_JJ activity_NN unrelated_JJ to_TO the_DT costs_NNS incurred_VBN over_IN that_DT period_NN :_: this_DT contrasts_VBZ with_IN the_DT UK_NNP GAAP_NNP treatment_NN ,_, where_WRB revenues_NNS are_VBP recognized_VBN as_IN costs_NNS are_VBP incurred_VBN ,_, using_VBG the_DT principles_NNS of_IN long-term_JJ contract_NN accounting_NN ._.
The_DT Group_NNP recognizes_VBZ revenue_NN on_IN the_DT manufacturing_NN portion_NN of_IN the_DT contract_NN as_IN smallpox_NN vaccine_NN is_VBZ delivered_VBN to_TO the_DT CDC_NNP and_CC all_DT risks_NNS and_CC rewards_NNS of_IN ownership_NN have_VBP transferred_VBN to_TO the_DT CDC_NNP ._.
Costs_NNS associated_VBN with_IN expected_VBN re-labelling_NN to_TO be_VB undertaken_VBN in_IN the_DT future_NN are_VBP being_VBG accrued_VBN as_IN smallpox_NN vaccine_NN is_VBZ delivered_VBN to_TO the_DT CDC_NNP ._.
Costs_NNS and_CC revenue_NN associated_VBN with_IN providing_VBG storage_NN or_CC vaccine_NN disposal_NN services_NNS are_VBP only_RB included_VBN when_WRB ,_, and_CC if_IN ,_, it_PRP is_VBZ deemed_VBN probable_JJ that_IN such_JJ services_NNS will_MD be_VB performed_VBN ._.
Compensation_NNP costs_NNS under_IN variable_JJ plan_NN accounting_NN for_IN stock_NN options_NNS and_CC SAYE_NNP plan_NN discount_NN Acambis_NNP has_VBZ granted_VBN stock_NN options_NNS to_TO employees_NNS that_WDT will_MD vest_NN upon_IN the_DT attainment_NN of_IN certain_JJ targets_NNS ._.
Under_IN UK_NNP GAAP_NNP ,_, there_EX is_VBZ no_DT accounting_NN for_IN these_DT grants_NNS after_IN the_DT initial_JJ grant_NN date_NN ._.
Under_IN US_NNP GAAP_NNP ,_, APB_NNP Opinion_NNP No._NN ._.
25_CD ,_, Accounting_NNP for_IN Stock_NNP Issued_NNP to_TO Employees_NNS APB25_NNP ,_, the_DT Company_NN would_MD be_VB required_VBN to_TO follow_VB variable_JJ plan_NN accounting_NN for_IN these_DT grants_NNS and_CC measure_NN compensation_NN expense_NN as_IN the_DT difference_NN between_IN the_DT exercise_NN price_NN and_CC the_DT fair_JJ market_NN value_NN of_IN the_DT stock_NN during_IN each_DT accounting_NN period_NN over_IN the_DT vesting_JJ period_NN of_IN the_DT options_NNS ._.
Increases_NNS in_IN fair_JJ market_NN value_NN of_IN the_DT stock_NN would_MD result_VB in_IN a_DT charge_NN to_TO operations_NNS and_CC decreases_VBZ in_IN the_DT fair_JJ market_NN value_NN of_IN the_DT stock_NN would_MD result_VB in_IN a_DT credit_NN to_TO operations_NNS ,_, subject_JJ to_TO the_DT cumulative_JJ amount_NN previously_RB expensed_VBN ._.
Under_IN UK_NNP GAAP_NNP ,_, Acambis_NNP has_VBZ taken_VBN advantage_NN of_IN the_DT exemption_NN provided_VBN by_IN UITF_NNP 17_CD ,_, not_RB to_TO recognize_VB any_DT compensation_NN charge_NN in_IN respect_NN of_IN options_NNS granted_VBN under_IN SAYE_NNP plans_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, in_IN accounting_NN for_IN new_JJ offers_NNS made_VBD since_IN 24_CD January_NNP 2002_CD ,_, Acambis_NNP would_MD follow_VB the_DT requirements_NNS of_IN pronouncement_NN EITF_NNP 00-23_CD Issues_NNS relating_VBG to_TO the_DT Accounting_NN for_IN Stock_NNP Compensation_NNP under_IN APB25_NNP and_CC FIN44_NNP Financial_NNP Accounting_NNP Standards_NNP Board_NNP Interpretation_NNP Number_NNP FIN_NNP 44_CD ,_, Accounting_NNP for_IN Certain_NNP Transactions_NNS Involving_NNP Stock_NNP Compensation_NNP ,_, FIN44_CD which_WDT does_VBZ not_RB permit_VB such_PDT an_DT exemption_NN in_IN respect_NN of_IN plans_NNS with_IN certain_JJ characteristics_NNS ._.
The_DT compensation_NN charge_NN under_IN US_NNP GAAP_NNP in_IN respect_NN of_IN such_JJ plans_NNS would_MD be_VB calculated_VBN as_IN the_DT difference_NN between_IN the_DT market_NN price_NN of_IN the_DT shares_NNS at_IN the_DT date_NN of_IN grant_NN and_CC the_DT exercise_NN price_NN of_IN the_DT option_NN and_CC would_MD be_VB recorded_VBN on_IN a_DT straight-line_JJ basis_NN over_IN the_DT savings_NNS period_NN ._.
The_DT table_NN below_IN shows_NNS the_DT additional_JJ charge_NN or_CC credit_NN that_WDT would_MD have_VB been_VBN made_VBN to_TO the_DT Group_NNP profit_NN and_CC loss_NN account_NN under_IN US_NNP GAAP_NNP ._.
Year_NN ended_VBD 31_CD December_NNP 2002 2001 2000 000_CD 000_CD 000_CD Charged_VBN to_TO the_DT Group_NNP profit_NN and_CC loss_NN account_NN 1,212_CD 5,210_CD 312_CD Provision_NNP against_IN own_JJ shares_NNS held_VBD Under_IN UK_NNP GAAP_NNP ,_, own_JJ shares_NNS held_VBN by_IN the_DT Acambis_NNP Employees_NNP Trustees_NNP Limited_NNP are_VBP accounted_VBN for_IN as_IN fixed_JJ asset_NN investments_NNS and_CC provisions_NNS made_VBN against_IN these_DT investments_NNS to_TO reduce_VB them_PRP to_TO the_DT recoverable_JJ amount_NN are_VBP charged_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
Under_IN US_NNP GAAP_NNP ,_, own_JJ shares_NNS are_VBP recorded_VBN at_IN cost_NN ,_, are_VBP not_RB reviewed_VBN for_IN impairment_NN and_CC are_VBP accounted_VBN for_IN within_IN shareholders_NNS equity_NN ._.
Purchase_NN price_NN accounting_NN for_IN in-process_JJ R&D_NNP and_CC goodwill_NN amortisation_NN During_IN 1999_CD ,_, Acambis_NNP acquired_VBD Acambis_NNP Inc._NNP ._.
Under_IN both_DT UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP ,_, goodwill_NN is_VBZ identified_VBN as_IN being_VBG the_DT amount_NN that_IN the_DT fair_JJ value_NN of_IN the_DT consideration_NN exceeds_VBZ the_DT fair_JJ value_NN of_IN assets_NNS acquired_VBN ._.
However_RB ,_, under_IN UK_NNP GAAP_NNP no_DT value_NN is_VBZ attributed_VBN to_TO in-process_JJ R&D_NNP ,_, which_WDT is_VBZ not_RB the_DT case_NN under_IN US_NNP GAAP_NNP ._.
Under_IN US_NNP GAAP_NNP ,_, in_IN accordance_NN with_IN APB_NNP Opinion_NNP No._NN ._.
17_CD ,_, Intangible_NNP Assets_NNPS ,_, in-process_JJ R&D_NNP is_VBZ separately_RB identified_VBN and_CC analyzed_VBN to_TO determine_VB the_DT fair_JJ market_NN value_NN at_IN the_DT date_NN of_IN acquisition_NN ._.
In-process_JJ R&D_NNP is_VBZ identified_VBN in_IN accordance_NN with_IN the_DT definition_NN within_IN Statement_NNP of_IN Financial_NNP Accounting_NNP Standard_NNP SFAS_NNP No._NN ._.
2_CD ,_, Accounting_NNP for_IN Research_NNP and_CC Development_NNP Costs_NNS ._.
Following_VBG identification_NN of_IN qualifying_VBG R&D_NNP projects_NNS ,_, their_PRP$ value_NN was_VBD determined_VBN by_IN estimating_VBG the_DT costs_NNS to_TO develop_VB the_DT purchased_VBN in-process_NN R&D_NNP into_IN commercially_RB viable_JJ products_NNS ,_, estimating_VBG the_DT resulting_VBG net_JJ cash_NN flows_VBZ from_IN the_DT projects_NNS and_CC discounting_VBG the_DT net_JJ cash_NN flows_VBZ to_TO their_PRP$ present_JJ value_NN ._.
As_IN a_DT result_NN of_IN the_DT valuation_NN of_IN in-process_JJ R&D_NNP under_IN US_NNP GAAP_NNP ,_, the_DT fair_JJ value_NN of_IN assets_NNS acquired_VBN is_VBZ different_JJ from_IN that_DT calculated_VBN under_IN UK_NNP GAAP_NNP ,_, resulting_VBG in_IN differing_VBG values_NNS of_IN goodwill_NN ._.
The_DT table_NN below_IN shows_NNS the_DT difference_NN in_IN the_DT goodwill_NN calculation_NN and_CC the_DT associated_VBN amortisation_NN charge_NN in_IN the_DT Group_NNP profit_NN and_CC loss_NN account_NN ._.
Under_IN US_NNP GAAP_NNP ,_, in-process_JJ R&D_NNP is_VBZ written_VBN off_RP to_TO the_DT profit_NN and_CC loss_NN account_NN when_WRB incurred_VBN ._.
Under_IN UK_NNP GAAP_NNP ,_, Acambis_NNP amortises_VBZ goodwill_NN on_IN a_DT straight-line_JJ basis_NN over_IN an_DT estimate_NN of_IN the_DT time_NN the_DT Group_NNP is_VBZ expected_VBN to_TO benefit_VB from_IN it_PRP ._.
Until_IN 1_CD January_NNP 2002_CD ,_, this_DT was_VBD also_RB Acambis_NNP accounting_NN policy_NN under_IN US_NNP GAAP_NNP ._.
Following_VBG the_DT provisions_NNS of_IN SFAS_NNP 142_CD ,_, Goodwill_NNP and_CC Other_JJ Intangible_NNP Assets_NNPS SFAS_NNP 142_CD ,_, the_DT carrying_VBG value_NN of_IN goodwill_NN in_IN US_NNP GAAP_NNP was_VBD frozen_VBN and_CC became_VBD subject_JJ to_TO annual_JJ impairment_NN reviews_NNS ._.
The_DT transitional_JJ impairment_NN review_NN carried_VBD out_RP on_IN adoption_NN of_IN SFAS_NNP 142_CD did_VBD not_RB reveal_VB any_DT indication_NN of_IN impairment_NN ._.
Year_NN ended_VBD 31_CD December_NNP 2002_CD Year_NN ended_VBD 31_CD December_NNP 2001_CD UK_NNP GAAP_NNP US_NNP GAAP_NNP UK_NNP GAAP_NNP US_NNP GAAP_NNP 000 000 000 000_CD Goodwill_NNP on_IN acquisition_NN included_VBD on_IN balance_NN sheet_NN cost_NN 18,055_CD 6,155_CD 18,055_CD 6,155_CD Amortisation_NNP brought_VBD forward_RB 3,210_CD 1,094_CD 2,006_CD 684_CD Amortisation_NNP charged_VBD to_TO Group_NNP profit_NN and_CC loss_NN account_NN for_IN the_DT year_NN 1,204_CD -_: 1,204_CD 410_CD Goodwill_NNP net_JJ book_NN value_NN 13,641_CD 5,061_CD 14,845_CD 5,061_CD Capitalisation_NNP of_IN interest_NN Under_IN UK_NNP GAAP_NNP ,_, Acambis_NNP accounting_NN policy_NN is_VBZ that_IN interest_NN is_VBZ not_RB capitalized_VBN ._.
US_NNP GAAP_NNP would_MD require_VB interest_NN incurred_VBN as_IN part_NN of_IN the_DT cost_NN of_IN constructing_VBG fixed_JJ assets_NNS to_TO be_VB capitalized_VBN and_CC amortised_VBN over_IN the_DT life_NN of_IN the_DT asset_NN ._.
39_CD 40_CD NOTES_NNS TO_TO GROUP_NNP FINANCIAL_NNP STATEMENTS_NNP 31_CD December_NNP 2002_CD 29_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD Reconciliation_NNP of_IN net_JJ loss_NN from_IN UK_NNP GAAP_NNP to_TO US_NNP GAAP_NNP Based_VBD on_IN the_DT differences_NNS detailed_VBN above_IN ,_, the_DT following_VBG table_NN shows_VBZ the_DT reconciliation_NN of_IN the_DT Groups_NNS net_JJ loss_NN for_IN the_DT past_JJ three_CD years_NNS :_: Year_NN ended_VBD 31_CD December_NNP 2002 2001 2000 000_CD 000_CD 000_CD Net_JJ profit_NN loss_NN as_IN reported_VBN under_IN UK_NNP GAAP_NNP 9,575_CD 12,427_CD 11,074_CD Adjustments_NNS for_IN :_: Revenue_NN recognition_NN 24,124_CD 1,995_CD 570_CD Compensation_NNP costs_NNS credit_NN under_IN variable_JJ plan_NN accounting_NN for_IN stock_NN options_NNS and_CC SAYE_NNP plan_NN discount_NN 1,212_CD 5,210_CD 312_CD Provision_NNP against_IN own_JJ shares_NNS held_VBD 420_CD --_: Amortisation_NNP charge_NN for_IN goodwill_NN 1,204_CD 794_CD 794_CD Capitalisation_NNP of_IN interest_NN 560_CD -_: -_: Net_JJ loss_NN as_IN reported_VBN under_IN US_NNP GAAP_NNP before_IN cumulative_JJ effect_NN of_IN accounting_NN change_NN 13,577_CD 14,848_CD 11,162_CD Cumulative_JJ effect_NN of_IN accounting_NN change_NN :_: revenue_NN recognition_NN -_: -_: 2,572_CD Net_JJ loss_NN as_IN reported_VBN under_IN US_NNP GAAP_NNP after_IN cumulative_JJ effect_NN of_IN accounting_NN change_NN 13,577_CD 14,848_CD 13,734_CD Loss_NN per_IN share_NN under_IN US_NNP GAAP_NNP Under_IN US_NNP GAAP_NNP ,_, the_DT Group_NNP would_MD compute_VB loss_NN per_IN share_NN under_IN SFAS_NNP No._NN ._.
Under_IN SFAS_NNP 128_CD ,_, basic_JJ net_JJ loss_NN per_IN ordinary_JJ share_NN is_VBZ computed_JJ using_VBG the_DT weighted_JJ average_JJ number_NN of_IN shares_NNS of_IN common_JJ stock_NN outstanding_JJ during_IN the_DT period_NN ._.
Under_IN US_NNP GAAP_NNP ,_, diluted_VBD net_JJ loss_NN per_IN ordinary_JJ share_NN for_IN Acambis_NNP is_VBZ the_DT same_JJ as_IN basic_JJ net_JJ loss_NN per_IN ordinary_JJ share_NN ,_, as_IN the_DT effects_NNS of_IN the_DT Companys_NNPS potential_JJ ordinary_JJ share_NN equivalents_NNS are_VBP anti-dilutive_JJ ._.
Under_IN UK_NNP GAAP_NNP the_DT basis_NN of_IN calculation_NN is_VBZ the_DT same_JJ ._.
Because_IN the_DT Group_NNP has_VBZ recorded_VBN a_DT net_JJ profit_NN under_IN UK_NNP GAAP_NNP ,_, certain_JJ securities_NNS which_WDT are_VBP dilutive_JJ under_IN UK_NNP GAAP_NNP are_VBP anti-dilutive_JJ under_IN US_NNP GAAP_NNP ._.
The_DT net_JJ loss_NN per_IN share_NN under_IN US_NNP GAAP_NNP is_VBZ presented_VBN below_IN :_: Year_NN ended_VBD 31_CD December_NNP 2002 2001 2000 000_CD 000_CD 000_CD Basic_JJ loss_NN per_IN ordinary_JJ share_NN in_IN pence_NN before_IN cumulative_JJ effect_NN of_IN accounting_NN change_NN 14.1_CD 16.3_CD 14.0_CD Basic_JJ loss_NN per_IN share_NN in_IN pence_NN of_IN cumulative_JJ effect_NN of_IN accounting_NN change_NN -_: -_: 3.2_CD Basic_JJ loss_NN per_IN share_NN in_IN pence_NN 14.1_CD 16.3_CD 17.2_CD Shares_NNS used_VBN in_IN computing_VBG basic_JJ loss_NN per_IN ordinary_JJ share_NN 96,101,507_CD 91,027,463_CD 79,638,484_CD Diluted_JJ loss_NN per_IN ordinary_JJ share_NN in_IN pence_NN 14.1_CD 16.3_CD 17.2_CD Shares_NNS used_VBN in_IN computing_VBG diluted_JJ loss_NN per_IN ordinary_JJ share_NN 96,101,507_CD 91,027,463_CD 79,638,484_CD Anti-dilutive_JJ securities_NNS ,_, not_RB included_VBN above_IN 3,100,226_CD 2,294,366_CD 1,565,251_CD Anti-dilutive_JJ securities_NNS represent_VBP stock_NN options_NNS outstanding_JJ ,_, which_WDT have_VBP not_RB been_VBN included_VBN in_IN the_DT calculation_NN of_IN loss_NN per_IN ordinary_JJ share_NN as_IN the_DT impact_NN of_IN including_VBG such_JJ shares_NNS in_IN the_DT calculation_NN of_IN loss_NN per_IN share_NN would_MD be_VB anti-dilutive_JJ ._.
Income_NN and_CC expense_NN transactions_NNS with_IN the_DT same_JJ party_NN In_IN accordance_NN with_IN EITF_NNP Issue_NNP 02-16_CD ,_, Accounting_NN by_IN a_DT Reseller_NNP for_IN Cash_NNP Consideration_NNP Received_VBD from_IN a_DT Vendor_NNP ,_, certain_JJ transactions_NNS with_IN the_DT same_JJ party_NN ,_, which_WDT are_VBP shown_VBN gross_JJ under_IN UK_NNP GAAP_NNP ,_, are_VBP netted_VBN under_IN US_NNP GAAP_NNP ._.
These_DT adjustments_NNS have_VBP no_DT impact_NN on_IN net_JJ income_NN ._.
The_DT individual_JJ line_NN items_NNS affected_VBN are_VBP cost_NN of_IN sales_NNS which_WDT under_IN US_NNP GAAP_NNP in_IN 2002_CD is_VBZ 48.0_CD m_NN and_CC R&D_NN costs_NNS included_VBD within_IN operating_NN expenses_NNS 2002_CD 21.5_CD m._NN Discontinued_VBN operations_NNS As_IN discussed_VBN in_IN note_NN 4_CD ,_, the_DT Group_NNP completed_VBD the_DT disposal_NN of_IN its_PRP$ interest_NN in_IN its_PRP$ drug_NN discovery_NN business_NN ,_, Mimetrix_NNP ,_, during_IN 2000_CD ._.
Under_IN US_NNP GAAP_NNP ,_, the_DT operating_NN results_NNS of_IN discontinued_VBN operations_NNS should_MD be_VB reported_VBN separately_RB in_IN a_DT single_JJ caption_NN after_IN income_NN from_IN continuing_VBG operations_NNS ,_, net_NN of_IN income_NN tax_NN effects_NNS ,_, for_IN all_DT periods_NNS presented_VBN ._.
This_DT presentation_NN difference_NN has_VBZ no_DT impact_NN on_IN the_DT net_JJ loss_NN for_IN the_DT periods_NNS presented_VBN ._.
Reconciliation_NNP of_IN shareholders_NNS equity_NN from_IN UK_NNP GAAP_NNP to_TO US_NNP GAAP_NNP As_IN at_IN 31_CD December_NNP 2002 2001 2000 000_CD 000_CD 000_CD Shareholders_NNS equity_NN as_IN reported_VBN under_IN UK_NNP GAAP_NNP 46,251_CD 27,660_CD 36,139_CD Goodwill_NNP 8,580_CD 9,784_CD 10,578_CD Revenue_NN recognition_NN cumulative_JJ 25,272_CD 1,147_CD 3,142_CD Capitalisation_NNP of_IN interest_NN 560_CD --_: Reclassification_NN of_IN net_JJ book_NN value_NN of_IN investment_NN in_IN Group_NNP shares_NNS 797_CD 1,252_CD 1,445_CD Shareholders_NNS equity_NN as_IN reported_VBN under_IN US_NNP GAAP_NNP 12,162_CD 15,477_CD 20,974_CD Group_NNP statement_NN of_IN cash_NN flows_VBZ The_DT Group_NNP statement_NN of_IN cash_NN flows_NNS prepared_VBN under_IN UK_NNP GAAP_NNP presents_VBZ substantially_RB the_DT same_JJ information_NN as_IN that_DT required_VBN under_IN US_NNP GAAP_NNP by_IN SFAS_NNP No._NN ._.
These_DT standards_NNS differ_VBP ,_, however_RB ,_, with_IN regard_NN to_TO classification_NN of_IN items_NNS within_IN the_DT statements_NNS and_CC the_DT definition_NN of_IN cash_NN and_CC cash_NN equivalents_NNS ._.
Under_IN UK_NNP GAAP_NNP ,_, cash_NN comprises_VBZ only_RB cash_NN in_IN hand_NN and_CC deposits_NNS repayable_JJ on_IN demand_NN ._.
Deposits_NNS are_VBP repayable_JJ on_IN demand_NN if_IN they_PRP can_MD be_VB withdrawn_VBN at_IN any_DT time_NN without_IN notice_NN and_CC without_IN penalty_NN or_CC if_IN a_DT maturity_NN or_CC period_NN of_IN notice_NN of_IN not_RB more_JJR than_IN 24_CD hours_NNS or_CC one_CD working_VBG day_NN has_VBZ been_VBN agreed_VBN ._.
Under_IN US_NNP GAAP_NNP ,_, cash_NN equivalents_NNS are_VBP short-term_JJ highly_RB liquid_JJ investments_NNS ,_, with_IN a_DT maturity_NN of_IN three_CD months_NNS or_CC less_JJR at_IN inception_NN ,_, that_WDT are_VBP readily_RB convertible_JJ to_TO known_JJ amounts_NNS of_IN cash_NN and_CC present_JJ insignificant_JJ risk_NN of_IN changes_NNS in_IN value_NN because_IN of_IN changes_NNS in_IN interest_NN rates_NNS ._.
Under_IN UK_NNP GAAP_NNP ,_, cash_NN flows_NNS are_VBP presented_VBN separately_RB for_IN operating_VBG activities_NNS ,_, returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN ,_, taxation_NN ,_, capital_NN expenditure_NN and_CC financial_JJ investment_NN ,_, management_NN of_IN liquid_JJ resources_NNS and_CC financing_NN activities_NNS ._.
US_NNP GAAP_NNP requires_VBZ only_RB three_CD categories_NNS of_IN cash_NN flow_NN activity_NN to_TO be_VB reported_VBN :_: operating_NN ,_, investing_VBG and_CC financing_VBG ._.
Cash_NN flows_VBZ from_IN taxation_NN and_CC returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN under_IN UK_NNP GAAP_NNP would_MD ,_, with_IN the_DT exception_NN of_IN dividends_NNS paid_VBN ,_, be_VB shown_VBN under_IN operating_VBG activities_NNS under_IN US_NNP GAAP_NNP ._.
The_DT payment_NN of_IN dividends_NNS and_CC the_DT payment_NN to_TO acquire_VB own_JJ shares_NNS treasury_NN stock_NN would_MD be_VB included_VBN as_IN a_DT financing_NN activity_NN under_IN US_NNP GAAP_NNP ._.
Management_NN of_IN liquid_JJ resources_NNS under_IN UK_NNP GAAP_NNP would_MD be_VB included_VBN as_IN cash_NN and_CC cash_NN equivalents_NNS under_IN US_NNP GAAP_NNP to_TO the_DT extent_NN that_IN the_DT amounts_NNS involved_VBN have_VBP a_DT maturity_NN of_IN less_JJR than_IN three_CD months_NNS and_CC are_VBP convertible_JJ into_IN known_JJ amounts_NNS of_IN cash_NN ._.
Summary_JJ statements_NNS of_IN cash_NN flow_NN presented_VBN under_IN US_NNP GAAP_NNP are_VBP given_VBN below_IN :_: Year_NN ended_VBD 31_CD December_NNP 2002 2001 2000 000_CD 000_CD 000_CD Net_JJ cash_NN used_VBN in_IN operating_VBG activities_NNS 5,459_CD 6,968_CD 8,782_CD Net_JJ cash_NN used_VBN in_IN investing_VBG activities_NNS 11,460_CD 5,803_CD 4,488_CD Net_JJ cash_NN provided_VBN by_IN used_VBN in_IN financing_NN activities_NNS 7,740_CD 16,987_CD 12,819_CD Effect_NN of_IN foreign_JJ exchange_NN on_IN cash_NN and_CC cash_NN equivalents_NNS 1,242_CD --_: Decrease_NN increase_NN in_IN cash_NN and_CC cash_NN equivalents_NNS 10,421_CD 15,822_CD 451_CD Opening_NN cash_NN and_CC cash_NN equivalents_NNS 22,093_CD 6,271_CD 6,722_CD Closing_NN cash_NN and_CC cash_NN equivalents_NNS 11,672_CD 22,093_CD 6,271_CD Statement_NN of_IN other_JJ comprehensive_JJ income_NN 2002 2001 2000 000_CD 000_CD 000_CD Net_JJ loss_NN 13,577_CD 14,848_CD 13,734_CD Other_JJ comprehensive_JJ income_NN :_: foreign_JJ currency_NN translation_NN adjustment_NN net_NN of_IN tax_NN 1,276_CD 314_CD 817_CD Total_JJ comprehensive_JJ income_NN 12,301_CD 15,162_CD 14,551_CD 41_CD 42_CD NOTES_NNS TO_TO GROUP_NNP FINANCIAL_NNP STATEMENTS_NNP 31_CD December_NNP 2002_CD 29_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD Recently_RB issued_VBN pronouncements_NNS In_IN June_NNP 2002_CD ,_, the_DT Financial_NNP Accounting_NNP Standards_NNP Board_NNP FASB_NNP issued_VBD SFAS_NNP No._NN ._.
146_CD ,_, Accounting_NNP for_IN costs_NNS associated_VBN with_IN exit_NN or_CC disposal_NN activities_NNS SFAS_NNP 146_CD ._.
SFAS_NNP Further_JJ information_NN required_VBN 146_CD addresses_NNS financial_JJ accounting_NN and_CC reporting_VBG for_IN costs_NNS associated_VBN with_IN exit_NN or_CC disposal_NN activities_NNS and_CC nullifies_NNS EITF_NNP 94-3_CD ,_, Liability_NN recognition_NN for_IN certain_JJ employee_NN by_IN Form_NN 20-F_JJ termination_NN benefits_NNS and_CC other_JJ costs_NNS to_TO exit_NN an_DT activity_NN including_VBG certain_JJ costs_NNS incurred_VBN in_IN a_DT restructuring_NN ._.
SFAS_NNP 146_CD requires_VBZ that_IN a_DT liability_NN for_IN a_DT cost_NN associated_VBN with_IN This_DT section_NN contains_VBZ the_DT an_DT exit_NN or_CC disposal_NN activity_NN be_VB recognized_VBN when_WRB the_DT liability_NN is_VBZ incurred_VBN ._.
Under_IN EITF_NNP 94-3_CD ,_, a_DT liability_NN for_IN an_DT exit_NN cost_NN was_VBD recognized_VBN at_IN the_DT date_NN of_IN the_DT commitment_NN to_TO an_DT information_NN that_IN the_DT US_NNP Securities_NNPS exit_NN plan_NN ._.
SFAS_NNP 146_CD states_NNS that_IN a_DT commitment_NN to_TO a_DT plan_NN ,_, by_IN itself_PRP ,_, does_VBZ not_RB create_VB an_DT obligation_NN that_WDT meets_VBZ the_DT definition_NN of_IN a_DT liability_NN ._.
Therefore_RB ,_, SFAS_NNP 146_CD eliminates_VBZ the_DT and_CC Exchange_NNP Commission_NNP requires_VBZ definition_NN and_CC requirement_NN for_IN recognition_NN of_IN exit_NN costs_NNS in_IN EITF_NNP 94-3_CD ._.
It_PRP also_RB established_VBD that_IN fair_JJ value_NN is_VBZ the_DT objective_NN for_IN initial_JJ measurement_NN of_IN the_DT liability_NN ._.
SFAS_NNP 146_CD is_VBZ in_IN a_DT Form_NN 20-F_NN that_WDT does_VBZ not_RB appear_VB to_TO be_VB applied_VBN prospectively_RB to_TO exit_NN or_CC disposal_NN activities_NNS initiated_VBN after_IN 31_CD December_NNP 2002_CD ._.
Management_NN does_VBZ not_RB expect_VB the_DT adoption_NN of_IN SFAS_NNP 146_CD to_TO have_VB a_DT material_NN elsewhere_RB in_IN our_PRP$ Annual_JJ Report_NNP ._.
effect_NN on_IN its_PRP$ consolidated_JJ financial_JJ statements_NNS ._.
In_IN November_NNP 2002_CD ,_, the_DT FASB_NNP issued_VBD FASB_NNP Interpretation_NNP Number_NNP FIN_NNP No._NN ._.
45_CD ,_, Guarantors_NNP accounting_NN and_CC disclosure_NN requirements_NNS for_IN guarantees_NNS ,_, including_VBG indirect_JJ guarantees_NNS of_IN indebtedness_NN of_IN others_NNS FIN_NNP 45_CD ._.
FIN_NNP 45_CD requires_VBZ the_DT guarantor_NN to_TO recognize_VB ,_, at_IN the_DT inception_NN of_IN a_DT guarantee_NN ,_, a_DT liability_NN for_IN the_DT fair_JJ value_NN of_IN the_DT obligation_NN undertaken_VBN in_IN issuing_VBG the_DT guarantee_NN ._.
It_PRP also_RB elaborates_VBZ on_IN the_DT disclosure_NN to_TO be_VB made_VBN by_IN a_DT guarantor_NN in_IN its_PRP$ financial_JJ statements_NNS about_IN its_PRP$ obligation_NN under_IN certain_JJ guarantees_NNS that_IN it_PRP has_VBZ issued_VBN and_CC to_TO be_VB made_VBN in_IN regard_NN of_IN product_NN warranties_NNS ._.
The_DT initial_JJ recognition_NN and_CC movement_NN provisions_NNS of_IN this_DT interpretation_NN are_VBP applicable_JJ on_IN a_DT prospective_JJ basis_NN to_TO guarantees_NNS issued_VBN or_CC modified_VBN after_IN 31_CD December_NNP 2002_CD ,_, while_IN the_DT provisions_NNS of_IN the_DT disclosure_NN requirements_NNS are_VBP effective_JJ for_IN financial_JJ statements_NNS of_IN interim_JJ or_CC annual_JJ periods_NNS ending_VBG after_IN 15_CD December_NNP 2002_CD ._.
Management_NN does_VBZ not_RB expect_VB the_DT adoption_NN of_IN FIN_NNP 45_CD to_TO have_VB a_DT material_NN effect_NN on_IN its_PRP$ consolidated_JJ financial_JJ statements_NNS ._.
In_IN November_NNP 2002_CD ,_, the_DT EITF_NNP reached_VBD a_DT consensus_NN on_IN Accounting_NN for_IN revenue_NN arrangements_NNS with_IN multiple_JJ deliverables_NNS Issue_NNP 00-21_CD ._.
This_DT addresses_NNS certain_JJ aspects_NNS of_IN the_DT accounting_NN by_IN a_DT vendor_NN for_IN arrangements_NNS under_IN which_WDT it_PRP will_MD perform_VB multiple_JJ revenue-generating_JJ activities_NNS ._.
Specifically_RB ,_, Issue_NNP 00-21_CD addresses_NNS how_WRB to_TO determine_VB whether_IN an_DT arrangement_NN involving_VBG multiple_JJ deliverables_NNS contains_VBZ more_JJR than_IN one_CD unit_NN of_IN accounting_NN and_CC how_WRB arrangement_NN consideration_NN should_MD be_VB measured_VBN and_CC allocated_VBN to_TO the_DT separate_JJ units_NNS of_IN accounting_NN in_IN the_DT arrangement_NN ._.
The_DT provisions_NNS of_IN Issue_NNP 00-21_CD are_VBP effective_JJ for_IN revenue_NN arrangements_NNS entered_VBD into_IN in_IN fiscal_JJ periods_NNS beginning_VBG after_IN 15_CD June_NNP 2003_CD ,_, with_IN early_JJ application_NN permitted_VBD ._.
Management_NNP have_VBP applied_VBN the_DT provisions_NNS of_IN EITF_NNP 00-21_CD to_TO existing_VBG multiple_JJ element_NN arrangements_NNS ._.
In_IN January_NNP 2003_CD ,_, the_DT FASB_NNP issued_VBD FIN_NNP No._NN ._.
46_CD ,_, Consolidation_NN of_IN variable_JJ interest_NN entities_NNS FIN_NNP 46_CD ._.
FIN_NNP 46_CD clarifies_VBZ the_DT application_NN of_IN Accounting_NNP Research_NNP Bulletin_NNP No._NN ._.
51_CD ,_, Consolidated_NNP financial_JJ statements_NNS ,_, to_TO certain_JJ entities_NNS in_IN which_WDT equity_NN investors_NNS do_VBP not_RB have_VB the_DT characteristics_NNS of_IN a_DT controlling_VBG financial_JJ interest_NN or_CC do_VB not_RB have_VB sufficient_JJ equity_NN at_IN risk_NN for_IN the_DT entity_NN to_TO finance_VB its_PRP$ activities_NNS without_IN additional_JJ subordinated_JJ financial_JJ support_NN from_IN other_JJ parties_NNS ._.
FIN_NNP 46_CD applies_VBZ immediately_RB to_TO variable_JJ interest_NN entities_NNS created_VBN after_IN 31_CD January_NNP 2003_CD ,_, and_CC to_TO variable_JJ interest_NN entities_NNS in_IN which_WDT an_DT enterprise_NN obtains_VBZ an_DT interest_NN after_IN that_DT date_NN ._.
It_PRP applies_VBZ in_IN the_DT first_JJ fiscal_JJ year_NN or_CC interim_JJ period_NN beginning_VBG after_IN 15_CD June_NNP 2003_CD ,_, to_TO variable_JJ interest_NN entities_NNS in_IN which_WDT an_DT enterprise_NN holds_VBZ a_DT variable_JJ interest_NN that_IN it_PRP acquired_VBD before_IN 1_CD February_NNP 2003_CD ._.
FIN_NNP 46_CD applies_VBZ to_TO public_JJ enterprises_NNS as_IN of_IN the_DT beginning_NN of_IN the_DT applicable_JJ interim_NN or_CC annual_JJ period_NN ._.
Management_NN does_VBZ not_RB expect_VB the_DT adoption_NN of_IN FIN_NNP 46_CD to_TO have_VB a_DT material_NN effect_NN on_IN its_PRP$ consolidated_JJ financial_JJ statements_NNS ._.
FURTHER_JJ INFORMATION_NN REQUIRED_NNP BY_NNP FORM_NNP 20-F_JJ unaudited_JJ Managements_NNS discussion_NN and_CC analysis_NN of_IN financial_JJ condition_NN and_CC results_NNS of_IN operations_NNS 4b_VBP Overview_NNP The_DT financial_JJ statements_NNS contained_VBD within_IN this_DT Annual_JJ Report_NNP and_CC Form_NN 20-F_NN have_VBP been_VBN prepared_VBN in_IN accordance_NN with_IN UK_NNP GAAP_NNP ._.
A_DT reconciliation_NN to_TO US_NNP GAAP_NNP is_VBZ set_VBN out_RP in_IN note_NN 29_CD to_TO the_DT financial_JJ statements_NNS ._.
The_DT principal_JJ differences_NNS between_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP accounting_NN arise_VB on_IN revenue_NN recognition_NN timing_NN differences_NNS which_WDT has_VBZ resulted_VBN in_IN lower_JJR revenue_NN being_VBG recorded_VBN under_IN US_NNP GAAP_NNP in_IN 2002_CD which_WDT will_MD reverse_VB in_IN 2003_CD and_CC 2004_CD ,_, accounting_VBG for_IN stock_NN options_NNS and_CC the_DT treatment_NN of_IN goodwill_NN ._.
These_DT differences_NNS are_VBP described_VBN within_IN note_NN 29_CD to_TO the_DT financial_JJ statements_NNS ._.
Critical_JJ accounting_NN policies_NNS The_DT preparation_NN of_IN our_PRP$ financial_JJ statements_NNS requires_VBZ us_PRP to_TO make_VB estimates_NNS and_CC judgments_NNS that_WDT affect_VBP the_DT reported_VBN amount_NN of_IN net_JJ assets_NNS at_IN the_DT date_NN of_IN our_PRP$ financial_JJ statements_NNS and_CC the_DT reported_VBN amounts_NNS of_IN revenues_NNS and_CC expenses_NNS during_IN the_DT period_NN ._.
Critical_JJ accounting_NN policies_NNS are_VBP those_DT that_WDT have_VBP a_DT significant_JJ impact_NN on_IN the_DT Group_NNP 's_POS results_NNS and_CC require_VB the_DT most_RBS difficult_JJ ,_, subjective_JJ or_CC complex_JJ judgments_NNS by_IN management_NN ._.
For_IN a_DT full_JJ description_NN of_IN our_PRP$ accounting_NN policies_NNS please_VB refer_VBP to_TO note_VB 1_CD ._.
Our_PRP$ critical_JJ accounting_NN policies_NNS include_VBP the_DT following_NN :_: Revenue_NN recognition_NN Revenue_NN on_IN long-term_JJ contracts_NNS is_VBZ recognized_VBN according_VBG to_TO estimates_NNS by_IN management_NN of_IN the_DT progress_NN of_IN the_DT contract_NN and_CC the_DT estimated_VBN total_NN costs_NNS ._.
This_DT requires_VBZ that_IN the_DT extent_NN of_IN progress_NN towards_IN completion_NN of_IN contracts_NNS may_MD be_VB estimated_VBN with_IN reasonable_JJ certainty_NN ._.
Revisions_NNS in_IN these_DT estimates_NNS may_MD cause_VB the_DT Group_NNP 's_POS revenues_NNS to_TO fluctuate_VB from_IN period_NN to_TO period_NN ._.
The_DT Group_NNP 's_POS US_NNP GAAP_NNP revenue_NN recognition_NN accounting_NN policy_NN for_IN multiple_JJ element_NN arrangements_NNS ,_, which_WDT is_VBZ described_VBN more_JJR fully_RB on_IN page_NN 38_CD ,_, requires_VBZ the_DT determination_NN of_IN the_DT fair_JJ value_NN of_IN the_DT individual_JJ elements_NNS of_IN multiple_JJ element_NN arrangements_NNS and_CC the_DT allocation_NN of_IN the_DT total_JJ contract_NN value_NN amongst_IN the_DT elements_NNS identified_VBD using_VBG the_DT relative_JJ fair_JJ value_NN method_NN ._.
Under_IN the_DT Group_NNP 's_POS UK_NNP GAAP_NNP accounting_NN policy_NN ,_, contracts_NNS are_VBP accounted_VBN for_IN as_IN long-term_JJ contracts_NNS and_CC are_VBP only_RB segmented_JJ into_IN multiple_JJ elements_NNS where_WRB the_DT Group_NNP is_VBZ capable_JJ of_IN attributing_VBG a_DT reliable_JJ fair_JJ value_NN to_TO each_DT element_NN by_IN reference_NN to_TO individual_JJ transactions_NNS which_WDT might_MD be_VB the_DT case_NN ,_, for_IN instance_NN ,_, where_WRB separate_JJ tenders_NNS were_VBD submitted_VBN for_IN each_DT element_NN ._.
The_DT Group_NNP therefore_RB makes_VBZ significant_JJ judgments_NNS in_IN determining_VBG whether_IN a_DT particular_JJ multiple_JJ element_NN arrangement_NN is_VBZ capable_JJ of_IN segmentation_NN under_IN the_DT requirements_NNS of_IN US_NNP GAAP_NNP and_CC following_VBG best_JJS practice_NN under_IN UK_NNP GAAP_NNP ._.
Where_WRB ,_, under_IN US_NNP GAAP_NNP ,_, segmentation_NN is_VBZ required_VBN ,_, significant_JJ assumptions_NNS are_VBP made_VBN in_IN selecting_VBG appropriate_JJ similar_JJ contracts_NNS to_TO provide_VB evidence_NN of_IN the_DT fair_JJ value_NN of_IN the_DT individual_JJ elements_NNS ._.
Changes_NNS in_IN estimates_NNS of_IN fair_JJ value_NN of_IN elements_NNS in_IN an_DT arrangement_NN would_MD have_VB a_DT significant_JJ impact_NN on_IN the_DT timing_NN of_IN revenue_NN recognition_NN ._.
Differences_NNS in_IN revenue_NN recognition_NN policies_NNS under_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP give_VBP rise_NN to_TO a_DT significant_JJ reconciling_NN adjustment_NN ._.
The_DT size_NN and_CC direction_NN of_IN this_DT reconciling_NN amount_NN in_IN the_DT reconciliation_NN of_IN UK_NNP to_TO US_NNP GAAP_NNP net_JJ income_NN will_MD vary_VB considerably_RB from_IN period_NN to_TO period_NN based_VBN on_IN the_DT nature_NN of_IN contract_NN activity_NN in_IN the_DT period_NN ._.
Deferred_JJ tax_NN The_DT Group_NNP has_VBZ significant_JJ brought_VBN forward_RB operating_VBG losses_NNS in_IN a_DT particular_JJ tax_NN jurisdiction_NN ,_, against_IN which_WDT ,_, at_IN 31_CD December_NNP 2002_CD ,_, the_DT Group_NNP has_VBZ maintained_VBN a_DT full_JJ valuation_NN allowance_NN ._.
In_IN determining_VBG the_DT appropriateness_NN of_IN this_DT valuation_NN allowance_NN ,_, estimates_NNS are_VBP made_VBN of_IN the_DT Group_NNP 's_POS ability_NN to_TO use_VB these_DT losses_NNS ,_, based_VBN on_IN the_DT estimated_VBN taxable_JJ profit_NN or_CC loss_NN in_IN that_DT jurisdiction_NN ,_, which_WDT include_VBP estimates_NNS of_IN future_JJ revenues_NNS and_CC costs_NNS ,_, as_RB well_RB as_IN the_DT jurisdiction_NN in_IN which_WDT they_PRP will_MD arise_VB ._.
Revisions_NNS in_IN these_DT estimates_NNS may_MD cause_VB the_DT valuation_NN allowance_NN recorded_VBN and_CC the_DT Group_NNP 's_POS tax_NN charge_NN to_TO fluctuate_VB from_IN period_NN to_TO period_NN ._.
Valuation_NN of_IN long-lived_JJ assets_NNS and_CC goodwill_NN Depreciation_NN and_CC amortisation_NN rates_NNS are_VBP determined_VBN based_VBN on_IN management_NN estimates_NNS of_IN the_DT expected_VBN useful_JJ economic_JJ lives_NNS of_IN the_DT assets_NNS concerned_VBN ._.
The_DT most_RBS appropriate_JJ life_NN is_VBZ determined_VBN separately_RB for_IN each_DT asset_NN on_IN acquisition_NN ,_, subject_JJ to_TO prescribed_VBN ranges_NNS of_IN asset_NN lives_NNS ,_, as_IN disclosed_VBN in_IN note_NN 1_CD to_TO the_DT financial_JJ statements_NNS ._.
Changes_NNS to_TO the_DT useful_JJ lives_NNS selected_VBN could_MD have_VB a_DT material_NN impact_NN on_IN the_DT Group_NNP 's_POS net_JJ profit_NN ._.
The_DT Group_NNP assesses_VBZ the_DT carrying_VBG value_NN of_IN long-lived_JJ assets_NNS and_CC goodwill_NN whenever_WRB events_NNS or_CC changes_NNS in_IN circumstances_NNS indicate_VBP that_IN such_JJ carrying_VBG value_NN may_MD not_RB be_VB recoverable_JJ ._.
When_WRB we_PRP determine_VBP that_IN the_DT carrying_VBG value_NN of_IN long-lived_JJ assets_NNS and_CC goodwill_NN may_MD not_RB be_VB recoverable_JJ ,_, we_PRP measure_VBP any_DT impairment_NN based_VBN on_IN a_DT projected_VBN discounted_JJ cash_NN flow_NN method_NN using_VBG a_DT discount_NN rate_NN determined_VBN by_IN our_PRP$ management_NN to_TO be_VB commensurate_JJ with_IN the_DT risk_NN inherent_JJ in_IN our_PRP$ current_JJ business_NN model_NN ._.
This_DT review_NN is_VBZ based_VBN upon_IN our_PRP$ projections_NNS of_IN anticipated_JJ timing_NN and_CC amount_NN of_IN future_JJ cash_NN flows_NNS and_CC appropriate_JJ discount_NN rates_NNS ._.
While_IN we_PRP believe_VBP that_IN our_PRP$ assumptions_NNS are_VBP appropriate_JJ ,_, such_JJ estimates_NNS and_CC assumptions_NNS could_MD differ_VB materially_RB from_IN actual_JJ results_NNS and_CC accordingly_RB result_VB in_IN a_DT material_NN impact_NN on_IN the_DT carrying_VBG value_NN of_IN long-lived_JJ assets_NNS and_CC goodwill_NN ._.
5a_JJ Results_NNS of_IN operations_NNS 5d_VBD The_DT information_NN contained_VBD within_IN the_DT financial_JJ review_NN on_IN pages_NNS 14_CD and_CC 15_CD covers_VBZ the_DT results_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD prepared_VBN under_IN UK_NNP GAAP_NNP compared_VBD to_TO the_DT prior_JJ year_NN ended_VBD 31_CD December_NNP 2001_CD ._.
The_DT following_VBG information_NN compares_VBZ the_DT results_NNS under_IN UK_NNP GAAP_NNP for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2001_CD to_TO the_DT prior_JJ year_NN ended_VBD 31_CD December_NNP 2000_CD ,_, and_CC the_DT Groups_NNS financial_JJ position_NN at_IN 31_CD December_NNP 2002_CD and_CC 2001_CD ._.
2001_CD year_NN versus_IN 2000_CD year_NN The_DT financial_JJ results_NNS for_IN the_DT year_NN 2000_CD include_VBP data_NNS for_IN the_DT three-month_JJ period_NN ended_VBD 31_CD March_NNP 2000_CD for_IN the_DT discontinued_VBN operation_NN of_IN Mimetrix_NNP Limited_NNP ._.
Turnover_NN for_IN the_DT year_NN 2001_CD was_VBD 8.9_CD m_NN 2000_CD 6.3_CD m_NN ,_, which_WDT comprised_VBD R&D_NNP funding_VBG primarily_RB from_IN ongoing_JJ contracts_NNS with_IN the_DT CDC_NNP and_CC Aventis_NNP Pasteur_NNP ._.
The_DT increase_NN in_IN revenues_NNS reflects_VBZ a_DT full_JJ year_NN of_IN revenue_NN receivable_NN from_IN the_DT first_JJ contract_NN with_IN the_DT CDC_NNP in_IN 2001_CD compared_VBN to_TO only_RB three_CD months_NNS in_IN 2000_CD ._.
5c_JJ Expenditure_NN on_IN R&D_NNP increased_VBD in_IN 2001_CD to_TO 17.7_CD m_NN 2000_CD 12.7_CD m._FW There_EX was_VBD an_DT increase_NN in_IN the_DT number_NN of_IN product_NN programs_NNS ,_, each_DT of_IN which_WDT has_VBZ continued_VBN to_TO advance_VB towards_IN the_DT next_JJ stage_NN of_IN development_NN and_CC or_CC clinical_JJ trials_NNS ._.
Our_PRP$ share_NN of_IN the_DT expenditure_NN on_IN the_DT H._NNP pylori_NN joint_JJ venture_NN with_IN Aventis_NNP Pasteur_NNP was_VBD lower_JJR in_IN 2001_CD at_IN 0.4_CD m_NN 2000_CD 2.1_CD m_NN ,_, as_IN expenditure_NN on_IN the_DT project_NN was_VBD largely_RB restricted_VBN to_TO continuing_VBG a_DT number_NN of_IN small_JJ clinical_JJ trials_NNS ._.
43_CD 44_CD FURTHER_NNP INFORMATION_NNP REQUIRED_NNP BY_IN FORM_NNP 20-F_JJ unaudited_JJ Results_NNS of_IN operations_NNS continued_VBD Administrative_JJ costs_NNS increased_VBN during_IN 2001_CD to_TO 3.5_CD m_NN 2000_CD 2.9_CD m_NN ,_, primarily_RB as_IN a_DT result_NN of_IN expansion_NN of_IN the_DT Companys_NNP activities_NNS ,_, in_IN particular_JJ the_DT reactivation_NN of_IN the_DT manufacturing_NN facility_NN ._.
Administrative_JJ costs_NNS include_VBP 1.2_CD m_JJ 2000_CD 1.2_CD m_NN of_IN amortisation_NN of_IN the_DT goodwill_NN which_WDT arose_VBD as_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN Acambis_NNP Inc._NNP in_IN 1999_CD ._.
Interest_NN receivable_NN decreased_VBD marginally_RB to_TO 0.9_CD m_NN in_IN 2001_CD 2000_CD 1.0_CD m_NN ,_, primarily_RB as_IN a_DT result_NN of_IN lower_JJR rates_NNS of_IN interest_NN available_JJ in_IN the_DT period_NN ._.
Interest_NN payable_JJ of_IN 0.2_CD m_NN 2000_CD 0.2_CD m_NN ,_, relating_VBG entirely_RB to_TO the_DT Arilvax_NNP overdraft_NN facility_NN ,_, remained_VBD constant_JJ ._.
During_IN 2001_CD ,_, an_DT exchange_NN loss_NN of_IN 0.1_CD m_NN 2000_CD 0.3_CD m_NN arose_VBD as_IN a_DT result_NN of_IN the_DT revaluation_NN of_IN the_DT amount_NN outstanding_JJ under_IN the_DT US_NNP dollar-denominated_JJ Arilvax_NNP facility_NN ._.
In_IN accordance_NN with_IN FRS_NNP 11_CD ,_, Impairment_NN of_IN Fixed_NNP Assets_NNPS and_CC Goodwill_NNP ,_, during_IN 2001_CD the_DT Group_NNP recorded_VBD an_DT exceptional_JJ loss_NN of_IN 0.4_CD m_NN 2000_CD 0.7_CD m_NN relating_VBG to_TO the_DT impairment_NN write-down_NN of_IN the_DT investment_NN held_VBN in_IN Medivir_NNP AB_NNP ,_, which_WDT the_DT Group_NNP acquired_VBD on_IN the_DT sale_NN of_IN the_DT Mimetrix_NNP business_NN in_IN 2000_CD ._.
During_IN 2001_CD ,_, the_DT Group_NNP elected_VBD to_TO claim_VB an_DT R&D_NNP tax_NN credit_NN of_IN 0.1_CD m_NN 2000_CD nil_NN in_IN relation_NN to_TO qualifying_VBG R&D_NNP expenditure_NN in_IN the_DT UK_NNP ._.
The_DT net_JJ loss_NN for_IN the_DT year_NN increased_VBD to_TO 12.4_CD m_NN 2000_CD 11.1_CD m_NN ,_, primarily_RB as_IN a_DT result_NN of_IN increased_VBN R&D_NNP and_CC operating_VBG costs_NNS at_IN the_DT new_JJ Massachusetts_NNP manufacturing_NN facility_NN ,_, both_DT of_IN which_WDT were_VBD largely_RB offset_VBN by_IN increased_VBN turnover_NN ._.
Liquidity_NN and_CC capital_NN resources_NNS 4b_VBP 5b_JJ The_DT Group_NNP had_VBD aggregate_JJ cash_NN and_CC liquid_JJ resources_NNS of_IN 11.8_CD m_NN at_IN 31_CD December_NNP 2002_CD 2001_CD 22.2_CD m_NN ,_, a_DT decrease_NN of_IN 10.4_CD m_NN since_IN the_DT start_NN of_IN the_DT year_NN 2001_CD increase_NN of_IN 1.1_CD m._FW During_IN the_DT year_NN ,_, Acambis_NNP received_VBD 7.7_CD m_NN 2001_CD 4.3_CD m_NN from_IN the_DT issue_NN of_IN new_JJ shares_NNS ,_, primarily_RB being_VBG attributable_JJ to_TO the_DT net_JJ proceeds_NNS receivable_NN from_IN the_DT third_JJ equity_NN subscription_NN for_IN new_JJ shares_NNS by_IN Baxter_NNP ._.
Cash_NN used_VBN by_IN operations_NNS during_IN the_DT year_NN ,_, principally_RB to_TO support_VB R&D_NNP ,_, was_VBD 6.2_CD m_NN 2001_CD 8.0_CD m._NN During_IN 2002_CD ,_, Acambis_NNP made_VBD additions_NNS of_IN short_JJ leasehold_JJ land_NN and_CC buildings_NNS of_IN 5.0_CD m_NN 2001_CD 6.9_CD m_NN ,_, 2000_CD 0.2_CD m_NN ,_, acquired_VBD 4.5_CD m_NN of_IN laboratory_NN and_CC manufacturing_NN equipment_NN 2001_CD 2.7_CD m_NN ,_, 2000_CD 0.1_CD m_NN and_CC 1.2_CD m_NN of_IN office_NN equipment_NN 2001_CD 0.4_CD m_NN ,_, 2000_CD 0.1_CD m._NN Additions_NNS in_IN 2002_CD and_CC 2001_CD were_VBD primarily_RB in_IN relation_NN to_TO the_DT reactivation_NN of_IN our_PRP$ manufacturing_NN facility_NN ._.
From_IN incorporation_NN through_IN to_TO 31_CD December_NNP 2002_CD ,_, Acambis_NNP has_VBZ financed_VBN its_PRP$ operations_NNS primarily_RB from_IN equity_NN issuances_NNS totalling_VBG 85.3_CD m_NN ,_, licence_NN fees_NNS and_CC milestone_NN payments_NNS totalling_VBG 3.1_CD m_NN ,_, R&D_NNP contract_NN fees_NNS and_CC sales_NNS of_IN product_NN totalling_VBG 101.6_CD m_NN and_CC government_NN grants_NNS totalling_VBG 3.9_CD m._FW At_IN 31_CD December_NNP 2002_CD ,_, Acambis_NNP held_VBD investments_NNS in_IN Medivir_NNP AB_NNP market_NN value_NN at_IN 31_CD December_NNP 2002_CD of_IN 0.3_CD m_NN ,_, 2001_CD 0.4_CD m_NN and_CC in_IN Acambis_NNP ordinary_JJ shares_NNS through_IN Acambis_NNP Employee_NNP Share_NNP Ownership_NNP Trust_NNP market_NN value_NN at_IN 31_CD December_NNP 2002_CD of_IN 1.6_CD m_NN ,_, 2001_CD 2.5_CD m._FW Under_IN the_DT terms_NNS of_IN the_DT strategic_JJ alliance_NN set_VBN up_RP with_IN Baxter_NNP in_IN 2000_CD ,_, the_DT Group_NNP has_VBZ received_VBN cash_NN of_IN 7.0_CD m_NN in_IN 2002_CD 2001_CD 3.5_CD m_NN ,_, 2000_CD 10.4_CD m_NN in_IN exchange_NN for_IN new_JJ shares_NNS in_IN Acambis_NNP ._.
On_IN 27_CD March_NNP 2003_CD ,_, the_DT Group_NNP issued_VBD 4.6_CD million_CD new_JJ shares_NNS in_IN relation_NN to_TO the_DT final_JJ subscription_NN to_TO Baxter_NNP ._.
At_IN 31_CD December_NNP 2002_CD ,_, the_DT balance_NN on_IN the_DT Arilvax_NNP overdraft_NN facility_NN was_VBD 4.3_CD m_NN $_$ 7.0_CD m_NN 2001_CD 4.8_CD m_NN ,_, 2000_CD 4.7_CD m._NN At_IN 31_CD December_NNP 2002_CD ,_, the_DT Group_NNP did_VBD not_RB have_VB any_DT undrawn_JJ borrowing_NN facilities_NNS in_IN respect_NN of_IN this_DT overdraft_NN facility_NN 2001_CD nil_NN ,_, 2000_CD nil_NN ._.
Given_VBN certain_JJ circumstances_NNS ,_, this_DT facility_NN which_WDT is_VBZ fully_RB described_VBN in_IN note_NN d_SYM on_IN page_NN 46_CD ,_, Evans_NNP Vaccines_NNP agreement_NN ,_, may_MD be_VB repayable_JJ within_IN one_CD year_NN ._.
In_IN December_NNP 2001_CD ,_, the_DT Group_NNP secured_VBN lease_NN financing_NN for_IN up_RB to_TO $_$ 40m_CD c._NN 28m_CD with_IN Baxter_NNP in_IN respect_NN of_IN Acambis_NNP manufacturing_VBG facility_NN ._.
At_IN 31_CD December_NNP 2002_CD ,_, the_DT Group_NNP had_VBD an_DT outstanding_JJ liability_NN of_IN 14.0_CD m_NN $_$ 22.5_CD m_NN under_IN this_DT financing_NN facility_NN 2001_CD 14.3_CD m_NN ,_, 2000_CD nil_NN ._.
At_IN 31_CD December_NNP 2002_CD ,_, the_DT Group_NNP had_VBD $_$ 17.5_CD m_NN c._NN 10.9_CD m_NN undrawn_JJ borrowing_NN facilities_NNS in_IN respect_NN of_IN this_DT financing_NN facility_NN 2001_CD 13.2_CD m_NN ,_, 2000_CD nil_NN ._.
The_DT repayment_NN terms_NNS of_IN this_DT facility_NN are_VBP described_VBN in_IN note_NN 18_CD ._.
The_DT Group_NNP does_VBZ not_RB have_VB any_DT other_JJ financial_JJ liabilities_NNS ._.
Since_IN inception_NN ,_, Acambis_NNP cash_NN expenditures_NNS have_VBP exceeded_VBN revenues_NNS on_IN an_DT annualised_JJ basis_NN ._.
Acambis_NNP future_JJ capital_NN requirements_NNS will_MD depend_VB on_IN many_JJ factors_NNS ,_, including_VBG ,_, but_CC not_RB limited_VBN to_TO ,_, the_DT expenditure_NN required_VBN to_TO maintain_VB the_DT manufacturing_NN facility_NN ,_, the_DT progress_NN of_IN R&D_NNP programs_NNS ,_, pre-clinical_JJ and_CC clinical_JJ testing_NN ,_, the_DT time_NN and_CC costs_NNS involved_VBN in_IN obtaining_VBG regulatory_JJ approvals_NNS ,_, the_DT cost_NN of_IN filing_NN ,_, prosecuting_VBG and_CC enforcing_VBG any_DT patent_NN claims_NNS and_CC other_JJ intellectual_JJ property_NN rights_NNS ,_, competing_VBG technological_JJ and_CC market_NN developments_NNS ,_, changes_NNS in_IN Acambis_NNP existing_VBG research_NN relationships_NNS ,_, the_DT ability_NN of_IN Acambis_NNP to_TO establish_VB collaborative_JJ arrangements_NNS ,_, receipt_NN of_IN any_DT licence_NN fees_NNS and_CC royalties_NNS and_CC the_DT acquisition_NN of_IN additional_JJ facilities_NNS and_CC capital_NN expenditure_NN ._.
As_IN a_DT result_NN of_IN the_DT $_$ 40m_CD c._NN 28m_JJ lease-financing_NN facility_NN secured_VBN in_IN December_NNP 2001_CD and_CC the_DT award_NN of_IN the_DT second_JJ US_NNP Government_NNP smallpox_NN vaccine_NN contract_NN in_IN November_NNP 2001_CD ,_, Acambis_NNP believes_VBZ that_IN there_EX will_MD be_VB sufficient_JJ cash_NN to_TO fund_VB its_PRP$ operations_NNS through_IN 2003_CD ._.
Changes_NNS in_IN R&D_NNP plans_NNS or_CC other_JJ events_NNS affecting_VBG Acambis_NNP operations_NNS ,_, however_RB ,_, may_MD result_VB in_IN accelerated_VBN or_CC unexpected_JJ expenditures_NNS ._.
If_IN additional_JJ funds_NNS are_VBP raised_VBN by_IN issuing_VBG equity_NN securities_NNS ,_, dilution_NN to_TO existing_VBG shareholders_NNS may_MD result_VB and_CC future_JJ investors_NNS may_MD be_VB granted_VBN rights_NNS superior_JJ to_TO those_DT of_IN existing_VBG shareholders_NNS ._.
5c_JJ Collaboration_NNP agreements_NNS 10c_VBP a_DT US_NNP CDC_NNP agreements_NNS The_DT Group_NNP has_VBZ been_VBN awarded_VBN two_CD distinct_JJ contracts_NNS Contract_NNP 1_CD and_CC Contract_NNP 2_CD by_IN the_DT CDC_NNP to_TO develop_VB and_CC manufacture_VB smallpox_NN vaccines_NNS for_IN the_DT purposes_NNS of_IN countering_VBG the_DT threat_NN of_IN bioterrorism_NN ._.
Contract_NN 1_CD This_DT contract_NN was_VBD awarded_VBN in_IN September_NNP 2000_CD ,_, and_CC incorporates_VBZ two_CD elements_NNS ._.
First_RB ,_, to_TO develop_VB a_DT new_JJ smallpox_NN vaccine_NN and_CC ,_, second_JJ ,_, to_TO produce_VB and_CC maintain_VB a_DT stockpile_NN of_IN vaccine_NN doses_NNS ._.
At_IN the_DT time_NN of_IN the_DT initial_JJ award_NN ,_, the_DT estimated_VBN value_NN of_IN the_DT 20-year_JJ contract_NN was_VBD $_$ 343m_CD ._.
This_DT value_NN made_VBD certain_JJ assumptions_NNS concerning_VBG price_NN per_IN dose_NN ,_, the_DT shelf-life_NN of_IN the_DT vaccine_NN and_CC that_IN a_DT 40_CD milliondose_JJ stockpile_NN of_IN the_DT vaccine_NN would_MD be_VB produced_VBN and_CC maintained_VBN for_IN 20_CD years_NNS ._.
Following_VBG the_DT terrorist_JJ events_NNS of_IN 11_CD September_NNP 2001_CD ,_, the_DT CDC_NNP issued_VBD a_DT change_NN order_NN ,_, increasing_VBG the_DT number_NN of_IN doses_NNS to_TO be_VB delivered_VBN from_IN 40_CD million_CD to_TO 54_CD million_CD ._.
The_DT Group_NNP is_VBZ required_VBN to_TO sustain_VB a_DT production_NN capability_NN throughout_IN the_DT 20-year_JJ life_NN of_IN the_DT contract_NN ,_, both_DT to_TO replace_VB outdated_JJ doses_NNS and_CC to_TO be_VB able_JJ to_TO respond_VB to_TO increased_VBN demand_NN as_IN required_VBN ._.
The_DT exclusive_JJ commercial_JJ rights_NNS to_TO the_DT smallpox_NN vaccine_NN developed_VBN under_IN this_DT contract_NN with_IN the_DT CDC_NNP are_VBP retained_VBN by_IN Acambis_NNP ._.
During_IN 2002_CD ,_, the_DT Group_NNP recorded_VBD turnover_NN of_IN 17.7_CD m_NN 2001_CD 5.7_CD m_NN ,_, 2000_CD 0.6_CD m_NN for_IN R&D_NN costs_NNS incurred_VBN by_IN the_DT Group_NNP and_CC funded_VBN by_IN the_DT CDC_NNP ._.
Contract_NN 2_CD In_IN November_NNP 2001_CD ,_, Acambis_NNP was_VBD awarded_VBN a_DT second_JJ contract_NN by_IN the_DT CDC_NNP to_TO develop_VB ,_, manufacture_VB ,_, deliver_VB and_CC store_VB 155_CD million_CD doses_NNS of_IN smallpox_NN vaccine_NN ._.
The_DT value_NN of_IN this_DT contract_NN ,_, which_WDT carries_VBZ a_DT fixed_JJ price_NN ,_, is_VBZ $_$ 428m_CD c._NN 270m_NN ._.
Contract_NN 2_CD is_VBZ divided_VBN into_IN two_CD principal_JJ components_NNS :_: funding_NN to_TO take_VB the_DT vaccine_NN through_IN clinical_JJ trials_NNS to_TO US_NNP FDA_NNP licensure_NN :_: and_CC manufacture_NN of_IN the_DT vaccine_NN ._.
The_DT funding_NN for_IN the_DT R&D_NNP element_NN will_MD be_VB received_VBN over_IN 2002_CD and_CC 2003_CD ,_, whereas_IN the_DT funding_NN for_IN the_DT manufacture_NN will_MD be_VB received_VBN on_IN delivery_NN of_IN the_DT vaccine_NN ,_, which_WDT started_VBD during_IN 2002_CD and_CC is_VBZ continuing_VBG into_IN 2003_CD ._.
Turnover_NN has_VBZ been_VBN recorded_VBN in_IN 2002_CD in_IN relation_NN to_TO this_DT contract_NN of_IN 58.2_CD m_NN 2001_CD nil_NN ,_, 2000_CD nil_NN ._.
b_NN Baxter_NNP agreements_NNS In_IN December_NNP 2000_CD ,_, Acambis_NNP entered_VBD into_IN the_DT following_VBG series_NN of_IN agreements_NNS with_IN Baxter_NNP :_: Baxter_NNP has_VBZ invested_VBN 27.8_CD m_NN in_IN new_JJ Acambis_NNP equity_NN ._.
This_DT subscription_NN was_VBD payable_JJ in_IN four_CD instalments_NNS between_IN December_NNP 2000_CD and_CC ,_, at_IN the_DT latest_JJS ,_, June_NNP 2003_CD at_IN an_DT average_JJ price_NN of_IN 130p_CD per_IN share_NN ._.
The_DT first_JJ instalment_NN of_IN 10.4_CD m_NN was_VBD made_VBN in_IN December_NNP 2000_CD ,_, the_DT second_JJ instalment_NN of_IN 3.5_CD m_NN was_VBD made_VBN in_IN June_NNP 2001_CD and_CC the_DT third_JJ instalment_NN of_IN 7.0_CD m_NN was_VBD made_VBN in_IN June_NNP 2002_CD ._.
The_DT fourth_JJ and_CC final_JJ instalment_NN totalling_VBG 7.0_CD m_NN was_VBD made_VBN on_IN 27_CD March_NNP 2003_CD :_: Acambis_NNP has_VBZ the_DT exclusive_JJ rights_NNS to_TO manufacture_VB components_NNS of_IN certain_JJ of_IN Baxters_NNP vaccines_NNS at_IN Acambis_NNP manufacturing_VBG facility_NN :_: Acambis_NNP granted_VBD Baxter_NNP an_DT option_NN to_TO be_VB its_PRP$ marketing_NN partner_NN for_IN the_DT yellow_JJ fever_NN vaccine_NN ,_, Arilvax_NNP ,_, in_IN the_DT US_NNP subject_NN to_TO approval_NN from_IN PowderJect_NNP Pharmaceuticals_NNP plc_NN PowderJect_NNP :_: and_CC Baxter_NNP licensed_VBD to_TO Acambis_NNP the_DT rights_NNS to_TO use_VB Baxters_NNP novel_NN Vero-cell_NN technology_NN in_IN exchange_NN for_IN royalty_NN payments_NNS to_TO Baxter_NNP ._.
This_DT currently_RB applies_VBZ to_TO the_DT production_NN of_IN Acambis_NNP ChimeriVax-JE_NNP ,_, ChimeriVax-West_NNP Nile_NNP and_CC smallpox_JJ vaccines_NNS ._.
Under_IN the_DT terms_NNS of_IN the_DT agreement_NN entered_VBD into_IN in_IN December_NNP 2000_CD ,_, in_IN 2002_CD ,_, the_DT Group_NNP received_VBD income_NN of_IN 1.3_CD m_NN 2001_CD nil_NN in_IN relation_NN to_TO Baxters_NNP share_NN of_IN the_DT commissioning_VBG of_IN Acambis_NNP manufacturing_NN plant_NN ._.
This_DT income_NN has_VBZ been_VBN netted_VBN off_RP against_IN R&D_NNP costs_NNS on_IN the_DT face_NN of_IN the_DT profit_NN and_CC loss_NN account_NN ._.
No_DT turnover_NN was_VBD recorded_VBN in_IN 2002_CD 2001_CD nil_NN ,_, 2000_CD nil_NN under_IN this_DT agreement_NN ._.
In_IN November_NNP 2001_CD ,_, Acambis_NNP entered_VBD into_IN a_DT sub-contract_JJ with_IN Baxter_NNP for_IN the_DT purchase_NN of_IN crude_JJ bulk_NN smallpox_NN vaccine_NN and_CC the_DT subsequent_JJ assembly_NN of_IN various_JJ components_NNS into_IN multi-dose_JJ kits_NNS of_IN smallpox_NN vaccine_NN ._.
In_IN December_NNP 2001_CD ,_, Acambis_NNP entered_VBD into_IN a_DT long-term_JJ lease-finance_NN facility_NN with_IN Baxter_NNP in_IN respect_NN of_IN Acambis_NNP manufacturing_NN plant_NN ._.
Further_JJ details_NNS of_IN this_DT facility_NN are_VBP described_VBN within_IN Financial_NNP liabilities_NNS in_IN note_NN 20_CD ._.
In_IN December_NNP 2002_CD ,_, Acambis_NNP entered_VBD into_IN a_DT distribution_NN ,_, manufacturing_NN and_CC licence_NN agreement_NN with_IN Baxter_NNP ,_, giving_VBG Baxter_NNP exclusive_JJ distribution_NN rights_NNS for_IN ACAM2000_NNP smallpox_NN vaccine_NN in_IN all_DT countries_NNS of_IN the_DT world_NN excluding_VBG the_DT US_NNP and_CC the_DT UK_NNP ._.
In_IN 2002_CD ,_, turnover_NN of_IN 0.7_CD m_NN 2001_CD nil_NN ,_, 2000_CD nil_NN was_VBD recorded_VBN under_IN this_DT agreement_NN ._.
c_NN Aventis_NNP Pasteur_NNP agreements_NNS H._NNP pylori_NNS The_DT arrangements_NNS relating_VBG to_TO the_DT Joint_NNP Venture_NNP ,_, called_VBD Pasteur_NNP Mrieux-OraVax_NNP ,_, are_VBP described_VBN in_IN notes_NNS 14_CD d_SYM and_CC 27_CD ._.
The_DT Groups_NNS share_NN of_IN the_DT net_JJ liabilities_NNS of_IN Pasteur_NNP Mrieux-OraVax_NNP at_IN 31_CD December_NNP 2002_CD was_VBD 0.2_CD m_NN 2001_CD net_JJ assets_NNS of_IN 0.07_CD m_NN ,_, 2000_CD net_JJ liabilities_NNS of_IN 0.04_CD m._FW During_IN 2002_CD ,_, the_DT Group_NNP recorded_VBD turnover_NN of_IN 0.3_CD m_NN 2001_CD 0.5_CD m_NN ,_, 2000_CD 2_CD ._. ._.
4m_NN for_IN R&D_NN costs_NNS incurred_VBN by_IN the_DT Group_NNP and_CC funded_VBN by_IN Pasteur_NNP Mrieux-OraVax_NNP ._.
The_DT Group_NNP will_MD share_VB any_DT revenues_NNS from_IN sales_NNS of_IN the_DT final_JJ product_NN in_IN equal_JJ proportions_NNS with_IN Aventis_NNP Pasteur_NNP ._.
45_CD 46_CD FURTHER_NNP INFORMATION_NNP REQUIRED_NNP BY_IN FORM_NNP 20-F_JJ unaudited_JJ ChimeriVax-Dengue_NNP The_NNP Group_NNP has_VBZ a_DT licensing_NN and_CC collaboration_NN agreement_NN with_IN Aventis_NNP Pasteur_NNP to_TO employ_VB the_DT ChimeriVax_NNP technology_NN to_TO develop_VB a_DT vaccine_NN against_IN dengue_NN fever_NN ._.
Aventis_NNP Pasteur_NNP fully_RB funds_NNS all_DT R&D_NN costs_VBZ incurred_VBN on_IN the_DT project_NN ._.
Previously_RB ,_, Aventis_NNP Pasteur_NNP also_RB funded_VBD the_DT Groups_NNS Japanese_JJ encephalitis_NN project_NN ,_, the_DT rights_NNS for_IN which_WDT were_VBD returned_VBN to_TO Acambis_NNP during_IN 2000_CD ._.
During_IN 2002_CD ,_, the_DT Group_NNP has_VBZ recorded_VBN turnover_NN of_IN 3.3_CD m_NN 2001_CD 2.6_CD m_NN ,_, 2000_CD 3.0_CD m_NN for_IN R&D_NN costs_NNS incurred_VBN by_IN the_DT Group_NNP and_CC funded_VBN by_IN Aventis_NNP Pasteur_NNP under_IN this_DT agreement_NN ._.
The_DT Group_NNP has_VBZ the_DT ability_NN to_TO receive_VB clinical_JJ and_CC regulatory_JJ milestones_NNS through_IN to_TO product_NN licensure_NN in_IN addition_NN to_TO royalties_NNS on_IN sales_NNS of_IN the_DT actual_JJ product_NN ._.
d_LS Evans_NNP Vaccines_NNP agreement_NN In_IN September_NNP 1999_CD ,_, the_DT Group_NNP entered_VBD into_IN an_DT agreement_NN with_IN Medeva_NNP Pharma_NNP Limited_NNP to_TO obtain_VB regulatory_JJ approval_NN in_IN the_DT US_NNP for_IN Arilvax_NNP ._.
Medeva_NNP Pharma_NNP Limited_NNP assigned_VBN this_DT agreement_NN to_TO Evans_NNP Vaccines_NNP Limited_NNP ,_, a_DT wholly-owned_JJ subsidiary_NN of_IN PowderJect_NNP ,_, in_IN October_NNP 2000_CD ._.
The_DT Group_NNP is_VBZ funding_VBG 100_CD %_NN of_IN the_DT costs_NNS of_IN the_DT clinical_JJ trials_NNS and_CC regulatory_JJ submission_NN ._.
As_IN described_VBN in_IN note_NN 18_CD ,_, Creditors_NNPS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN ,_, the_DT costs_NNS are_VBP being_VBG partly_RB financed_VBN through_IN an_DT overdraft_NN facility_NN up_IN to_TO a_DT maximum_NN of_IN $_$ 7m_CD ,_, being_VBG underwritten_VBN by_IN PowderJect_NNP ._.
PowderJect_NNP has_VBZ granted_VBN to_TO Acambis_NNP 100_CD %_NN of_IN the_DT marketing_NN rights_NNS to_TO Arilvax_NNP in_IN the_DT US_NNP ,_, whilst_NN still_RB retaining_VBG an_DT option_NN to_TO buy_VB back_RB 50_CD %_NN of_IN the_DT profits_NNS from_IN the_DT US_NNP sales_NNS in_IN return_NN for_IN refunding_VBG to_TO the_DT Group_NNP the_DT costs_NNS the_DT Group_NNP has_VBZ incurred_VBN on_IN the_DT Arilvax_NNP program_NN ._.
No_DT turnover_NN was_VBD recorded_VBN in_IN 2002_CD 2001_CD nil_NN ,_, 1999_CD nil_NN under_IN this_DT agreement_NN ._.
10e_CD UK_NNP tax_NN consequences_NNS of_IN owning_VBG Acambis_NNP shares_NNS Taxation_NNP of_IN dividends_NNS There_EX is_VBZ no_DT withholding_NN tax_NN on_IN dividends_NNS paid_VBN by_IN a_DT UK_NNP company_NN ._.
Under_IN the_DT provisions_NNS of_IN the_DT income_NN tax_NN convention_NN currently_RB in_IN force_NN between_IN the_DT UK_NNP and_CC the_DT US_NNP ,_, a_DT US_NNP holder_NN who_WP is_VBZ an_DT individual_JJ or_CC a_DT corporate_JJ portfolio_NN holder_NN ,_, who_WP does_VBZ not_RB own_JJ 10_CD %_NN or_CC more_JJR of_IN the_DT Acambis_NNP shares_NNS a_DT Corporate_JJ Portfolio_NN Holder_NNP ,_, will_MD be_VB entitled_VBN to_TO receive_VB a_DT payment_NN from_IN the_DT UK_NNP Inland_NNP Revenue_NNP equal_JJ to_TO the_DT tax_NN credit_NN in_IN respect_NN of_IN the_DT dividend_NN the_DT Tax_NNP Treaty_NNP Payment_NN minus_CC a_DT withholding_NN of_IN 15_CD %_NN of_IN the_DT aggregate_NN of_IN the_DT dividend_NN and_CC the_DT tax_NN credit_NN one-ninth_NN of_IN the_DT dividend_NN ,_, meaning_VBG that_IN the_DT amount_NN of_IN the_DT withholding_NN will_MD effectively_RB eliminate_VB the_DT amount_NN of_IN Tax_NNP Treaty_NNP Payment_NN ._.
Thus_RB ,_, a_DT US_NNP individual_NN or_CC US_NNP Corporate_NNP Portfolio_NNP Holder_NNP who_WP is_VBZ entitled_VBN to_TO an_DT 80_CD dividend_NN paid_VBN by_IN Acambis_NNP will_MD receive_VB 80_CD ._.
UK_NNP taxation_NN of_IN capital_NN gains_NNS A_DT US_NNP holder_NN who_WP is_VBZ not_RB resident_JJ ,_, or_CC ordinarily_RB resident_JJ ,_, for_IN tax_NN purposes_NNS in_IN the_DT UK_NNP will_MD not_RB be_VB liable_JJ for_IN UK_NNP tax_NN on_IN capital_NN gains_NNS on_IN the_DT disposal_NN of_IN Acambis_NNP shares_NNS unless_IN the_DT US_NNP holder_NN carries_VBZ on_IN a_DT trade_NN ,_, profession_NN or_CC vocation_NN in_IN the_DT UK_NNP through_IN a_DT branch_NN or_CC agency_NN and_CC the_DT Acambis_NNP shares_NNS are_VBP or_CC have_VBP been_VBN used_VBN by_IN ,_, held_VBN by_IN ,_, or_CC acquired_VBN for_IN use_NN by_IN or_CC for_IN the_DT purposes_NNS of_IN such_JJ trade_NN ,_, profession_NN ,_, vocation_NN ,_, branch_NN or_CC agent_NN ._.
UK_NNP inheritance_NN tax_NN on_IN estates_NNS and_CC gifts_NNS The_DT estate_NN and_CC gift_NN tax_NN convention_NN in_IN force_NN between_IN the_DT US_NNP and_CC the_DT UK_NNP provides_VBZ that_IN the_DT UK_NNP tax_NN to_TO which_WDT the_DT convention_NN applies_VBZ is_VBZ capital_NN transfer_NN tax_NN and_CC that_IN it_PRP will_MD also_RB apply_VB to_TO identical_JJ or_CC substantially_RB similar_JJ taxes_NNS which_WDT are_VBP imposed_VBN subsequently_RB ._.
Capital_NNP transfer_NN tax_NN in_IN the_DT UK_NNP has_VBZ been_VBN replaced_VBN by_IN inheritance_NN tax_NN ._.
It_PRP is_VBZ understood_VBN that_IN ,_, in_IN practice_NN ,_, the_DT US_NNP tax_NN authorities_NNS and_CC the_DT UK_NNP Inland_NNP Revenue_NNP apply_VB the_DT convention_NN on_IN the_DT basis_NN that_WDT inheritance_NN tax_NN has_VBZ replaced_VBN capital_NN transfer_NN tax_NN as_IN the_DT tax_NN to_TO which_WDT the_DT convention_NN now_RB applies_VBZ ,_, although_IN the_DT convention_NN has_VBZ not_RB been_VBN amended_VBN to_TO that_DT effect_NN ._.
On_IN the_DT basis_NN of_IN that_DT practice_NN ,_, Acambis_NNP shares_NNS held_VBD in_IN the_DT US_NNP by_IN an_DT individual_NN who_WP is_VBZ domiciled_VBN for_IN the_DT purposes_NNS of_IN the_DT estate_NN and_CC gift_NN tax_NN convention_NN in_IN the_DT US_NNP and_CC is_VBZ not_RB for_IN the_DT purposes_NNS of_IN the_DT convention_NN a_DT national_JJ of_IN the_DT UK_NNP ,_, will_MD not_RB be_VB subject_JJ to_TO inheritance_NN tax_NN on_IN the_DT individuals_NNS death_NN or_CC on_IN a_DT transfer_NN of_IN the_DT Acambis_NNP shares_NNS during_IN the_DT individuals_NNS lifetime_NN ._.
However_RB ,_, special_JJ rules_NNS apply_VBP in_IN the_DT case_NN of_IN Acambis_NNP shares_NNS held_VBD in_IN trust_NN or_CC as_IN part_NN of_IN the_DT business_NN property_NN of_IN a_DT permanent_JJ establishment_NN in_IN the_DT UK_NNP or_CC related_VBN to_TO the_DT fixed_VBN base_NN in_IN the_DT UK_NNP of_IN a_DT person_NN providing_VBG independent_JJ personal_JJ services_NNS ._.
UK_NNP stamp_VB duty_NN and_CC stamp_VB duty_NN reserve_NN tax_NN Any_DT transfer_NN of_IN Acambis_NNP shares_NNS will_MD result_VB in_IN the_DT stamp_NN duty_NN liability_NN at_IN the_DT rate_NN of_IN 0.5_CD %_NN rounded_VBD to_TO the_DT nearest_JJS 5_CD of_IN the_DT consideration_NN which_WDT liability_NN is_VBZ generally_RB payable_JJ by_IN the_DT purchaser_NN of_IN the_DT Acambis_NNP shares_NNS ._.
There_EX is_VBZ no_DT charge_NN to_TO ad_NN valorem_NN stamp_NN duty_NN on_IN gifts_NNS ._.
On_IN a_DT transfer_NN of_IN Acambis_NNP shares_NNS from_IN a_DT nominee_NN to_TO the_DT beneficial_JJ owner_NN ,_, if_IN the_DT nominee_NN has_VBZ at_IN all_DT times_NNS held_VBD the_DT Acambis_NNP shares_NNS on_IN behalf_NN of_IN the_DT transferee_NN ,_, under_IN which_WDT no_DT beneficial_JJ interest_NN passes_VBZ and_CC which_WDT is_VBZ neither_RB a_DT sale_NN ,_, nor_CC arises_VBZ under_IN or_CC following_VBG a_DT contract_NN of_IN sale_NN ,_, nor_CC is_VBZ in_IN contemplation_NN of_IN sale_NN ,_, a_DT fixed_VBN 5_CD stamp_NN duty_NN will_MD be_VB payable_JJ ._.
Stamp_NN duty_NN reserve_NN tax_NN ,_, generally_RB at_IN a_DT rate_NN of_IN 0.5_CD %_NN on_IN the_DT consideration_NN ,_, is_VBZ currently_RB payable_JJ on_IN any_DT agreement_NN to_TO transfer_VB ordinary_JJ shares_NNS or_CC any_DT interest_NN therein_RB unless_IN :_: an_DT instrument_NN transferring_VBG the_DT shares_NNS is_VBZ duly_RB executed_VBN and_CC stamped_VBN within_IN the_DT appropriate_JJ time_NN limits_NNS :_: and_CC stamp_VB duty_NN ,_, generally_RB at_IN a_DT rate_NN of_IN 0.5_CD %_NN rounded_VBD to_TO the_DT nearest_JJS 5_CD of_IN consideration_NN or_CC part_NN thereof_RB ,_, is_VBZ paid_VBN ._.
